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ABSTRACT 
Both opioid and cannabinoid receptors belong to the large superfamily of GPCRs and 
play an important role in a variety of processes including pain, craving, neurodegeneration, 
metabolic regulation, anxiety and immune function. Therefore, recent advances and discoveries 
in opioid and cannabinoid receptors have paved the way for a very exciting future for opioid and 
cannabinoid receptors-based therapies to potentially treat a variety of conditions. 
However, the growing realizations of the complexity of these two receptors regulation in 
physiological and pathological conditions have discouraged the development of new 
therapeutics. So, it is important for us to identify new chemical scaffolds which act on opioid or 
cannabinoid receptors not only to probe these receptors in order to uncover the mystery of these 
two receptors but also to identify new leads for the development of new therapeutic agents.  
Natural products are substantially more diverse than combinatorial compounds and fungi-
derived natural products are unexplored and untapped domains for opioid and cannabinoid 
receptors-based drug discovery. In addition, fungi have a very successful record in serving as 
sources of leads within the pharmaceutical industry. Therefore, it is reasonable and feasible to 
identify new agents from fungi which act on opioid or cannabinoid receptors.  
Radioligand binding assays for opioid and cannabinoid receptors have been a useful tool 
for the discovery of novel agents. With the use of this assay, four fungi species were selected and 
subjected to bioassay-guided fractionation affording a total of twenty-nine compounds which 
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were identified using standard spectrometric and spectroscopic methods. Two new benzyl 
derivatives (1 and 2) and seven known compounds (3-9) were isolated and identified from the 
fungus Eurotium repens. Three new (10-12) and three known resorcylic acid lactones (13-15) 
were isolated from the fungus Neocosmospora sp. NRRL 22472. Three new (16-18) and ten 
known compounds (19-28) were isolated from the fungus Eupenicillium parvum.  
The research presented in this dissertation confirms the potential of fungi-derived natural 
products with binding affinities for opioid or cannabinoid receptors.  
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1. INTRODUCTION 
This chapter will provide some basic knowledge about opioid receptors, cannabinoid 
receptors and fungi-derived natural products with a focus on the biomedical potential of fungi-
derived natural products with activities on opioid or cannabinoid receptors.  
1.1. Opioid Receptors and Cannabinoid Receptors in Drug Discovery  
1.1.1. G Protein Coupled Receptors (GPCR) and Drug Discovery 
G protein-coupled receptors (GPCRs) consist of a large protein family of integral 
membrane proteins that possess seven membrane-spanning domains or transmembrane helices 
that sense molecules outside the cell and activate signal transduction pathways inside the cell and 
cellular responses. GPCRs are found only in eukaryotes including yeast, plants, 
choanoflagellates and animals (King et al., 2003). The GPCR class is by far the most abundant 
and therapeutically relevant among receptor classes which exist in humans. The total number of 
verified human GPCRs has continued to increase and now comprises at least 800 members 
(Gloriam et al., 2007).  There are a variety of the ligands that bind and activate these receptors. 
The ligands include neurotransmitters and hormones and vary in size from small molecules to 
peptides, to large proteins. There are different binding domains that depend on each receptor and 
its ligands located in the N terminal end and/or within the transmembrane domain. In addition, a 
series of allosteric binding sites have been studied and identified for GPCRs. A GPCR is 
supposed to exist in a conformational equilibrium between active and inactive biophysical states. 
The equilibrium can be shifted toward the active states by the binding of ligands to the receptor.  
There are two main signal transduction pathways involved in the G protein-coupled 
receptors: the cAMP signal pathway and the phosphatidylinositol signal pathway (Gilman 1987). 
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A ligand binds to the GPCR and then a conformational change in the GPCR occurs, which 
allows the ligand to act as a guanine nucleotide exchange factor (GEF). The activated GPCR can 
then activate an associated G-protein by exchanging its bound GDP for a GTP. The α subunit of 
G-protein with the bound GTP can then dissociate from the β and γ subunits and then affect 
intracellular signaling proteins or target functional proteins (Wettschureck and Offermanns, 
2005). 
GPCRs are associated with  a variety of physiological processes including autonomic 
nervous system transmission, regulation in immune system activity and inflammation, 
and behavioral and mood regulation (Alkhalfioui et al., 2009).  
GPCRs have become successful drug targets for the pharmaceutical industry. It is usually 
accepted that about 30% of marketed drug targets are GPCRs (Overington et al., 2006).  
1.1.2. Opioid Receptors in Drug Discovery 
1.1.2.1. Introduction of Opioid Receptors 
 Opioid receptors are members of a large superfamily of G protein-coupled receptors 
(GPCRs). They are activated by both endogenous opioid peptides and exogenous opioid drugs, 
such as morphine, which are not only among the most effective analgesics but also highly 
addictive drugs of abuse (Morou and Georgoussi, 2005). Opium is an extract of the poppy 
plant, Papaver somniferum. In the second century, Galen, a Greek physician, administered 
opium to patients for the relief of pain, asthma and congestive heart failure. In 1804, the German 
chemist Serturner isolated morphine (1) from opium. However, it was not until 1973 that 
morphine (1) was confirmed to target opioid receptors (Corbett et al., 2006). There are at least 
three opioid receptor subtypes which differ in ligands and pharmacology.  
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1.1.2.2. Opioid Receptors Subtypes 
                  Opioid-binding sites were first proposed in the 1950s (Beckett and Casy, 1954) and 
discovered in 1973 (Waldhoer et al., 2004). About thirty years of extensive pharmacological 
research have uncovered a variety of opioid receptor types. To date, three opioid receptors have 
been identified, the MOP (μ = mu for morphine), the KOP (κ = kappa for ketocyclazocine) and 
the DOP (δ = delta for deferens).  
1.1.2.2.1. µ (MOP) Receptor 
     The μ-opioid receptors (MOR) are a class of opioid receptors which have high affinity 
for endomorphin and beta-endorphin but low affinity for dynorphins. The μ receptor can be 
activated by a lot of ligands including endogenous opioid peptides and exogenous opioid drugs 
(Table 1.1). Activation of the μ receptor causes analgesia, sedation, slightly reduced blood 
pressure, and decreased bowel motility (Corbett et al., 2006).  
1.1.2.2.2. κ (KOP) Receptor 
     The κ (KOP) receptors are a type of opioid receptor which can highly bind the opioid 
peptide dynorphin (Table 1.1). κ-opioid receptors are found in the brain (hypothalamus, 
periaqueductal gray, and claustrum), spinal cord (substantia gelatinosa), and in pain neurons 
(Waldhoer et al., 2004).  
1.1.2.2.3. δ (DOP) Receptor 
     The δ-opioid receptors (MOR) are a class of opioid receptors which have high affinity for 
enkephalins (Table 1.1).  Activation of δ-opioid receptors can also lead to analgesia though the 
efficacy is less than that of µ receptor agonists (Waldhoer et al., 2004). 
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           1.1.2.2.4. Other Opioid Receptors 
                 Currently a variety of other opioid receptors have been identified or described on the 
basis of pharmacological profiles that did not match any of the MOP, DOP and KOP. The NOP 
receptor was first discovered in 1994 and it is distributed in brain and spinal cord. A ζ (zeta) 
receptor was identified and classified as an opioid growth factor receptor (OGFr) with no 
homology to the classical opioid receptors (Waldhoer et al., 2004). 
           Table 1.1 Selective opioid receptor ligand 
Receptor Endogenous peptides Agonists Antagonists 
MOP Endomorphin Cyprodime (2) 
  Dermorphin Morphine (1) Naloxonazine (3) 
  β-endorphin   
  β-neoendorphin     
DOP Leu5-Enkephalin BW373U86 (7) Naltriben (8) 
  Met5-Enkephalin Naltrindole (9) 
  Deltorphin 
KOP Dynorphin A Bremazocine (4) 
  Dynorphin B Ketocyclazocine (5) Nor-binaltorphimine (6)
  α-neoendorphin   
 
           1.1.2.3. Structures 
     Opioid receptors belong to the class A (Rhodopsin-like) family of G- protein-coupled 
receptors and are comprised of an extracellular N-terminal domain, seven transmembrane helical 
domains and an intracellular C-terminal tail. The crystal structure of rhodopsin confirms that the 
seven transmembrane helices of opioid receptors are arranged sequentially in a counterclockwise 
fashion so that a tight helical bundle is formed. This special structure provides a dynamic 
interface for the binding of various opioid ligands (Palczewski et al., 2000). The opioid receptors 
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are about 60% identical to each other with greatest homology in the transmembrane helices. 
However, there is the greatest diversity in their N and C termini as well as their extracellular 
loops.  
      
 
Figure 1.1 Selective opioid receptor agonists and antagonists 
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1.1.2.4. Functions 
         Opioid receptor activation by endogenous and exogenous ligands can lead to analgesia, 
respiratory depression, euphoria, feeding, the release of hormones, inhibition of gastrointestinal 
transit, and anxiety. Many selective opioid receptor agonists and antagonists have been 
identified so far (Figure 1.1) In general, MOP-R-selective or DOP-R-selective agonists are 
analgesic and rewarding, whereas agonists selective for KOP receptors are dysphoric. Morphine 
and other opioids are regarded as the best analgesics for the treatment of chronic pain. However 
the major limitation is the development of physiological tolerance and dependence. Tolence is a 
“substantial decrease in analgesic effects during prolonged drug administration”. Physiological 
dependence results in “the necessity for continued administration of increasing doses of drug to 
prevent the development of symptoms of opioid withdrawal” (Waldhoer et al., 2004).  
1.1.2.5. The Role of Opioid Receptors in Drug Discovery 
     Pain signals are conducted by C and Aδ fibers which have cell bodies within the dorsal 
root ganglia of the spinal cord and they release neurotransmitters that are received by second 
order neurons. In turn, these fibers cross the spinal cord, travel to the thalamus and release the 
pain signal to tertiary neurons which can send it to the somatosensory cortex. Here, the pain 
signal is interpreted and weighed, adding the affective component of pain. Throughout the 
different levels of pain perception, opioid receptors modulate the incoming pain information 
(Vanderah 2010).  
     μ, κ and δ opioid receptors are distributed in the regions associated with pain modulation. 
These three opioid agonists have been shown to activate pain inhibitory pathways in the central 
nervous system.  So far, the majority of clinically available opioid analgesics are μ-agonists 
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which are morphine (1) or its derivatives. However, morphine and its derivatives have a lot of 
side effects including tolerance and dependency. In order to meet the need for an efficacious 
analgesic without the side effects, people start to focus on other two opioid receptors. However, 
currently there are only a few pharmacologic agents that target κ receptors and none that target δ 
receptors. New research has provided insight into difficulties on the development of effective κ 
and δ opioid receptor agonists. For example, a state of inflammation may be required to make 
sure that δ opioid agonists are effective because δ opioid receptors should be induced to migrate 
to the surface of neuronal cells and thereby become accessible to δ opioid agonists. Studies have 
shown that δ opioid agonists can be used to treat inflammatory pain and malignant bone pain. 
Meanwhile, peripherally restricted κ opioid agonists have been studied to target κ opioid 
receptors which are located on visceral and somatic afferent nerves for the treatment of 
inflammatory, visceral, and neuropathic chronic pain. Recent studies indicated that peripherally 
restricted κ opioid receptor agonists produced the efficacy of these analgesics combined with a 
possible lower abuse potential and side effect burden than μ opioid receptor agonists. Therefore, 
δ and peripherally restricted κ opioid receptor agonists are promising targets for treating pain 
(Corbett et al., 2009). 
1.1.3. Cannabinoid Receptors in Drug Discovery 
1.1.3.1. Introduction of Cannabinoid Receptors 
     Cannabinoid receptors are members of a large superfamily of G protein-coupled 
receptors (GPCRs). The discovery of cannabinoid receptors is derived from marijuana. Since its 
explosive use in the late 1960s, Cannabis sativa, known as marijuana, has been one of the most 
widespread illicit drugs of abuse in the world (Adamas and Martin, 1996). However, the 
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medicinal use of Cannabis also has a long history (Williamson and Evans, 2000). As early as 
2600 B.C., Chinese people took Cannabis for the relief of cramps, and rheumatic and menstrual 
pain; however, the great therapeutic potential of Cannabis was not scientifically studied in the 
Western world until the nineteenth century. 
     The major psychoactive ingredient of cannabis was first isolated by Yechiel Gaoni and 
Raphael Mechoulam of the Weizmann Institute of Science in Rehovot, Israel, in 1964 and then 
identified as (-)- Δ9-tetrahydrocannabinol (THC) (10) in 1967 (Gaoni and Mechoulam, 1964). 
Two drugs that are based on THC have been used clinically. Dronabinol (Marinol®) (11) is a 
schedule III controlled substance that contains synthetic THC. Dronabinol (11) is approved for 
appetite stimulation in AIDS-related anorexia and it is also used for the treatment of 
chemotherapy-induced nausea and vomiting in patients who don’t respond to conventional 
antiemetic therapies. Nabilone (12) is a synthetic THC analogue and was being prescribed in the 
United States as an anti-emetic and appetite-stimulant to patients with cancer and AIDS (Walsh 
et al., 2003).  The potency of THC inspired scientists to uncover the mechanism of action of 
THC which acts via specific sites of action to produce its typical psychotropic effects. Labelling 
of HU-210 (13) which is a potent and enantiomerically pure THC analogue [3H] HU-210, and 
the development of the non-classical cannabinoid CP-55,940 (14) by Pfizer, led to the 
identification of plasma membrane cannabinoid receptors in 1988 (Devane et al., 1988). In 1990 
the serendipitous cloning of the first of such proteins, the CB1 receptor, resulted from the 
screening of an 'orphan' G-protein-coupled receptor (GPCR) with several possible ligands 
(Matsuda et al., 1990). In 1993 the CB2 receptor, another receptor for THC (10), was cloned 
(Munro et al., 1993) and in the early 1990s the first endogenous ligands for cannabinoid CB1 and 
CB2 receptors, the endocannabinoids, were isolated (Di Marzo and Fontona 1995; Devane et al., 
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1992; Mechoulam et al., 1995; Sugiura et al., 1995). All endocannabinoids are derivatives 
(amides, esters and even ethers) of long-chain polyunsaturated fatty acids, specifically 
arachidonic acid, and they exhibit different selectivity for the two cannabinoid receptor as well 
as for other molecular targets (McAllister and Glass, 2002; Di Marzo et al., 2002). The two best-
studied endocannabinoids are anandamide (N-arachidonoylethanolamine) (15) and 2-
arachidonoylglycerol (2-AG) (16). 
1.1.3.2. Cannabinoid Receptors Subtypes 
1.1.3.2.1. CB1 Receptor 
                CB1 is highly expressed in the brain, predominantly on neurons. The distribution of 
receptors   appears well conserved between species and correlates well with the known 
behavioral effects of cannabinoids. Thus, high levels of receptor are observed in the 
hippocampus, in basal ganglia output nuclei (globus pallidus and substantia nigra), 
the cerebellum, and cortical association regions, while moderate levels are observed in primary 
cortical regions, thalamic nuclei, striatum, and low levels in brain stem and spinal cord regions. 
This distribution of CB1 is consistent with the known physiological effects of cannabinoids, 
including impairment of short term memory formation, altered motor activity and anxiety 
(Herkenham et al., 1992; Glass et al., 1997). Detailed immunohistochemical studies have 
shown that CB1 is predominantly expressed presynaptically on axon terminals (Nyris et al., 
2005) and has a highly localised cellular distribution. Low receptor expression in a region may 
not represent a low level of activity in this region as it has been demonstrated in rat brain that 
greater amplification in signal transduction through the G-proteins may exist in some regions 
with relatively low expression (Breivogel et al., 1997). 
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Figure 1.2 Cannabinoid receptor agonists and antagonists 
           1.1.3.2.2. CB2 Receptor 
                CB2 receptors are mainly distributed in T cells of the immune system, in hematopoietic 
cells, and on macrophages and B cells (Pertwee 1997). They also occur in keratinocytes, 
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mouse pre-implantation embryos and peripheral nerve terminals. These receptors are supposed 
to play a role in nociception, or the perception of pain. In the brain, microglial cells express 
CB2 receptors. However, their role remains unclear.  
           1.1.3.2.3. Other Cannabinoid Receptors 
     The existence of additional cannabinoid receptors has long been suspected since the 
compounds such as abnormal cannabidiol  produces cannabinoid-like effects on blood 
pressure and inflammation but do not activate either CB1 or CB2 receptors (Jarai et al., 1999; Ho 
and Hiley, 2003; McHugh et al., 2008). Recently, some evidence supports the hypothesis that 
the N-arachidonoyl glycine (NAGly) receptor GPR18 is the abnormal cannabidiol receptor and 
additionally suggests that NAGly initiates directed microglial migration in the CNS through 
activation of GPR18 (McHugh et al., 2010). Other studies have suggested that the orphan 
receptor GPR55 should in fact be characterized as a cannabinoid receptor which is supported by 
the sequence homology at the binding site. Studies showed that GPR55 respondes to cannabinoid 
ligands (Ryberg et al., 2007; John et al., 2007). Additional evidence supports GPR55 as a 
distinct non-CB1/CB2 receptor that responds to a variety of both endogenous and exogenous 
cannabinoid ligands; some groups suggesting that GPR55 be categorized as a CB3 receptor 
(Overton et al., 2006). However another possible cannabinoid receptor has been discovered in 
the hippocampus, although its gene has not yet been cloned (de Fonseca et al., 2008). 
GPR119 would be a fifth possible cannabinoid receptor (Brown 2007). 
1.1.3.3. Structures 
     The amino acid sequences of CB1 and CB2 receptors are about 44% similar (Galiegue et 
al., 1995).  Amino acid similarity between the transmembrane regions of the two receptor 
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subtypes is approximately 68% (Gerard et al., 1991) and minor variations in each receptor have 
been identified.  
1.1.3.4. Functions 
     Cannabinoid receptors can mediate signal transduction which is associated with 
gastrointestinal activity, cardiovascular activity, pain and the maintenance of boss mass.  
     When the ligand bind to the receptor, the conformation of the receptor is changed and 
then the ligand-receptor complex activates multiple intracellular signal transduction pathways. 
At first, cannabinoid receptors were supposed to inhibit the enzyme adenylate cyclase (the 
production of the second messenger molecule cyclic AMP), and positively affect potassium 
channels (=Kir or IRK). However, cannabinoid receptor activation will result in a series of 
responses associated with other potassium ion channels, calcium channels, protein kinase A and 
C, Raf-1, ERK, JNK, p38, c-fos, c-jun (Demuth and Molleman, 2006). Many cannabinoid 
receptors agonists and antagonists have been identified so far (Figure 1.2).  
1.1.3.5. The Role of Cannabinoid Receptors in Drug Discovery 
1.1.3.5.1. CB1 Receptor and Obesity 
     According to the data from the World Health Organization (WHO), more than 70% of the 
population of United States and the United Kingdom is obese or overweight. Furthermore, the 
prevalence of obesity has increased worldwide by 75% since 1980 and obesity is defined as a 
global epidemic by WHO (Bray et al., 2006). Obesity can cause serious consequences for both 
individual and society because excessive bodyweight is now considered to be one of the most 
important risk factors associated with metabolic syndrome, which is a combination of risk factors 
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including glucose intolerance, hypertension, and dyslipidemia. This is responsible for increased 
prevalence of some severe diseases including diabetes ,cardiovascular diseases and cancers and 
led to more than 1 million deaths in Europe alone (O’Brien and Dixon, 2002; Abate 1999). The 
growing awareness of the medical problems that accompany obesity is driving people to find 
effective treatments. However, current treatment strategies including lifestyle change, dietary 
modifications and medicine are not managing the problem (Tsigos et al., 2008). Many molecular 
targets have been identified for the treatment of obesity. There are only two antiobesity drugs on 
the market: one is the monaminergic reuptake inhibitor sibutramine and another is the lipidase 
inhibitor orlistat (Van der Ploeg 2000; Szabo et al., 2009). However, both of them meet with 
moderate success owing to their limited weight-loss efficacy and some serious side effects, 
which push people to find new therapeutical targets.  
     Evidence suggests that activation of the endocannabinoid system can lead to the 
stimulation of appetite (Black 2004). Current studies support the concept that CB1 agonists 
adjust energy balance through shared central and peripheral mechanisms and CB1 antagonists 
have long-term efficacy for weight loss and improve lipid metabolism. Thus, this class of drugs 
becomes an exciting potential treatment for obesity. Rimonabant (17), also known as SR141716 
or Acomplia®, was the first CB1 antagonist reported. It is a diarylpyrazole and has strong 
affinity for CB1 receptors and little affinity for the CB2 receptor (Rinaldi-Carmona et al., 1994). 
It shows good inverse agonism both in vitro and in vivo preparations (Bouaboula et al., 1997; 
Pan et al., 1998). Many analogues of rimonabant have been synthesized and an SAR developed 
(Howlett et al., 2002). Other potent CB1 antagonists with different structures have been 
synthesized, for example, Taranabant (18) (Lin et al., 2006) and Otenabant (19) (Griffith et al., 
2009). However, substantial clinical evidence showed that CB1 antagonists might cause severe 
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psychiatric problems including depression, anxiety, and stress disorders; Rimonabant (17) was 
approved and launched in Europe in 2006, was withdrawn from the market in 2008. Taranabant 
(18) and otenabant (19) were suspended at the late clinical development stage (phase III) (Lin et 
al., 2006; Griffith et al., 2009). Some evidence indicate that CB1 receptors located in the 
peripheral tissues including fat and liver might regulate food intake and energy balance as 
effectively as those appearing in the central nervous system (CNS) (Pagotto et al., 2006; Storr et 
al., 2007). It is widely accepted that severe psychiatric problems would be significantly 
alleviated when compounds act solely on receptors in the peripheral system rather than the CNS. 
Recently, scientists took an alternative to develop peripherally restricted CB1 antagonists, which 
is totally different from the conventional brain-penetrant CB1 antagonists and could not 
penetrate blood−brain barrier (BBB). This strategy achieved a certain degree of success because 
less CNS toxic profile and sufficient weight-reduction efficacy have been observed with 
rimonabant-mimicking analogues acting exclusively on peripheral CB1 receptor (LoVerme et 
al., 2009; Wu et al., 2009).  
1.1.3.5.2. CB1 and Neurodegeneration 
     The anatomical localization of CB1 receptors in the brain has been extensively studied by 
several groups (Glass et al., 1997; Rodriguez et al., 2001; Pickel et al., 2004; Herkenham et al., 
1991). These studies have shown that CB1 is predominantly located in the pre-synaptic 
membrane of GABAergic and glutamatergic synapses. Within these sites CB1 controls the 
release of the respective neurotransmitter from the pre-synaptic boutons (Hoffman and Lupica, 
2000). CB1 is abundant in basal ganglia nuclei and this region is particularly susceptible to the 
neuronal cell death related to the progression of Huntington's disease (HD). It is now well 
accepted that loss of CB1 in the globus pallidus and striatum are amongst the earliest molecular 
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changes known in human HD (Glass et al., 2000). Combined with the known neuroprotective 
effects of cannabinoid agonists and the consequence of CB1 loss during excitotoxicity it was 
proposed that neurons that lose their protective CB1 receptors during HD may be more 
vulnerable. Thus, it has been hypothesized that rescuing these receptors or preventing their loss 
may be advantageous and delay neuronal death, which has yet to be proven and the underlying 
molecular mechanisms that mediate the selective loss of CB1 are not known.  
     More and more evidence supports the hypothesis that the cannabinoid system may be 
involved in the progression of other neurodegenerative conditions including multiple sclerosis 
(MS), epilepsy, Parkinson's disease, Alzheimer's and several other conditions where neuro-
inflammatory components exacerbate progression (Baker et al., 2007; Ashton et al., 2007; 
Lastres-Becker et al., 2005; Ramirez et al., 2005; Pryce et al., 2003). For example, abnormal 
CB1 and CB2 receptors were found to highly express in close proximity to senile plaques in the 
brains of individuals with Alzheimer's disease. CB1 expression was reduced as a function of 
neuronal cell loss around the plaques whereas CB2 expression was increased in cells identified 
as microglia, with CB1 neuronal loss greater in areas of high numbers of activated microglial 
cells. This insightful correlation was probed further using a rat Alzheimer's model and evidence 
showed that cannabinoid agonists could effectively prevent microglial activation and the 
cognitive impairment associated with the neuronal cell death in the disease. These are promising 
findings and much work has yet to be conducted to understand the roles of cannabinoids in the 
early stages of brain damage especially with regard to effects on vascular blood flow, modulation 
of brain glial cells, regulation of cannabinoid receptor expression (loss of CB1 and elevation of 
CB2) and production of the endocannabinoid ligands proximal to the damaged tissue. 
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1.1.3.5.3. CB1 and Craving 
     Another area of excitement for the use of CB1 antagonists is in the treatment of drug 
abuse. A link between the endocannabinoids and drug abuse has long been found on animal 
studies (Le Foll and Goldberg, 2005). A large number of laboratory experiments indicated a 
reciprocal relationship between the motivational or rewarding aspects of endogenous opioids and 
the endocannabinoids. Specifically, the rewarding properties of opioids could be attenuated by 
CB1 antagonists and the rewarding properties of opioids are absent in CB1 knockout mice 
(Fattore et al., 2004). Furthermore, experiments on heroin-treated rats showed that reinstatement 
was enhanced by CB1 receptor agonists, and decreased by CB1 receptor antagonists. 
Interestingly, this effect of CB1 receptor antagonists was most noticable with less favorable 
response ratios, that is, when more effort is required to receive a heroin injection. Conversely, 
opioid receptor blockade and knockout of mu opioid receptors can decrease the rewarding effects 
of THC.  
     The endocannabinoid system has a role in the reinforcing effects of alcohol. CB1 receptor 
activation enhances alcohol consumption while blockage of these receptors decreases 
consumption and deletion of the receptors reduces alcohol-induced conditioned place preference 
(CPP) (Beardsley and Thomas, 2005). 
     The usefulness of CB1 antagonism in smoking cessation has been noted in the 
STRATUS-US trial (Cleland et al., 2004). A short (10 week) clinical trial with 787 moderate 
cigarette smokers was conducted to test the role of CB1 antagonism in smoking cessation. Those 
with rimonabant at 20 mg per day were almost twice (36% versus 20%) as likely to have 
sustained abstinence during the last four weeks of the trial compared to the placebo group. The 
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rimonabant group was found to also lose approximately half a pound of weight during treatment. 
However, the placebo group gained almost two and half pounds. The disparity in weight change 
was more obvious in obese patients. It is particularly interesting that most smoking cessation 
therapies cause weight gain after cessation. 
     Another potential application of CB1 blockade is the treatment of alcohol abuse which 
was supported by strong preclinical evidence (Mechoulam and Parker, 2003; Basavarajappa and 
Hungund, 2002). A clinical trial on the efficacy of rimonabant in alcoholism sponsored by the 
National Institute on Alcohol Abuse and Alcoholism (NIAAA) is now underway. Although 
financial factors probably decrease enthusiasm for conducting clinical trials on the effectiveness 
of CB1 antagonists in heroin or cocaine abuse, it is likely that they will be evaluated for efficacy 
in other “craving” disorders if CB1 antagonists are approved for clinical use. 
     One important factor to be considered in the application of CB1 blockade for the 
treatment of craving-based disorders is whether it will retain its effectiveness during prolonged 
treatment. Thus, substantial evidence is required to dertermine if CB1 antagonism will be an 
effective long-term strategy for the treatment of craving disorders. 
1.1.3.5.4. CB2 Receptor in the Central Nervous System and Inflammation 
     The discovery of the peripheral CB2 receptors in the brain of rodents and humans under 
specific pathological conditions may prove to be amongst the most important discoveries in the 
cannabinoid field in the past 10 years. The primary reason why CB2 expression in the brain may 
be extremely important is the hypothesis that its function is associated with suppressing the 
activity of resident brain immune cells (microglia and astrocytes) and as such has been suggested 
18 
 
as a new immuno-modulatory target for the clinical treatment of several neurological states 
(Ashton and Glass, 2007).  
     The presence of CB2 in the central nervous system was first reported in the spinal cord of 
rats with chronic neuropathic pain associated with peripheral nerve damage. More recent studies 
have measured CB2 receptors protein levels in several mouse and rat brain injury and disease 
models. All of these studies indicated that the up-regulation of CB2 was in cells with a 
microglial phenotype. In humans, CB2 is up-regulated in cells with a microglial phenotype in 
individuals with Alzheimer's disease, Down's syndrome, HIV, multiple sclerosis and in gliomal 
tumours. There have been a number of cell-based studies that have demonstrated that activation 
of CB2 receptors regulates microglial proliferation, migration, chemotaxis, and inflammatory 
functions. In addition, two in vitro models employing co-cultures of microglia with neurons or 
with organotypic hippocampal slice cultures have convincingly demonstrated the neuroprotective 
properties of microglial CB2 receptors (Benito et al., 2008).  
1.1.3.5.5. CB2 Receptor in the Spinal Cord and Neuropathic Pain 
     Neuropathic pain is defined as one type of pain which is caused by the lesion or 
dysfunction of the nervous system. In the world, as much as 7% to 8% of the population is 
affected and in the United States, more than two million people suffer from neuropathic pain 
(Foley 2003). Treatment of neuropathic pain is currently difficult and challenging because 
common causes are particularly complex, including diabetic neuropathy, nerve compression 
syndromes, postherpetic or trigeminal neuralgia, stroke, shingles, multiple sclerosis, spinal cord 
injury, cancer and HIV infection (Eisenberg et al., 2005). Current treatments include anti-
convulsants, tricyclic antidepressants, and NMDA receptor antagonists. All have a poor 
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therapeutic ratio, and the development of new drugs to treat neuropathic pain is of urgent clinical 
concern.  
     Selective CB2 agonists are effective in some of animal models, particularly of 
inflammatory pain. CB2 agonists may reduce neuropathic pain via CB2 receptors in microglia in 
the dorsal root ganglion and in the spinal cord dorsal horn. Expression of CB2 is up-regulated in 
these cells in models of neuropathic pain. CB2 agonists suppress inflammation in spinal cord 
slices that have been treated with capsaicin (Anand et al., 2009). It has also been shown that 
intrathecal injection of the selective CB2 agonist JWH-015 (20) can reduce post-operative 
hyperalgesia in the ipsilateral paw in rats (Beltramo 2009). Another CB2-selective agonist PRS-
211,375 (Cannabinor, Pharmos Corporation) is currently in Phase II clinical trials as an analgesic 
and the company reports that next-generation CB2-selective compounds are also being 
developed (www.pharmos.com). 
1.1.3.5.6. CB Receptors and Cancer 
     In 1975, cannabinoids was found to inhibit tumor growth and reduce viability of lung 
cancer cells in vitro as well as in vivo (Munson et al., 1975). However, we know little about the 
mechanism of action of CB receptor ligands for their anticancer activity until these years. Recent 
data indicated a protective function of the endocannabinoid system in cancer cells (Bifulo et al., 
2007; Guzman et al., 2003; Storr et al., 2007).  Both CB1 and CB2 agonists were found to inhibit 
the growth and invasiveness of several types of cancer cells and they could cause a variety of 
processes from mitosis and apoptosis to angiogenesis, migration and metastasis (Lzzo et al., 
2008; Di Marzo 2008).  Current studies showed that the interaction of CB1/CB2 agonists with 
receptors could lead to a series of signaling pathways where ceramide, AKT and ERK are likely 
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to be key mediators in the induction of apoptosis and the inhibition of cancer cells growth (Oesch 
and Gertsch, 2009). However, both the role of cannabinoid receptors in tumourigenesis and the 
molecular mechanisms of anticancer action of cannabinoid receptors need to be elucidated.  
1.2. Fungi-Derived Natural Products in Drug Discovery 
1.2.1. The Evolution of Natural Products 
     Metabolites are the intermediates and products of metabolism and they can be 
categorized into two basic types: primary and secondary metabolites. Natural products are 
generally referred to as secondary metabolite not essential for normal growth, development or 
reproduction.  Secondary metabolites usually have no obvious or direct effect on the producing 
organism, though in an indirect way a number of secondary metabolites have proven to be 
essential for the survival of some specific organisms in that they have deterrent effects on 
predators, or competitors.  In the biosynthesis of secondary metabolites there are four principle 
building blocks: acetate, mevalonate, shikimate and amino acids. However, most of these 
intermediates are also used for the production of primary metabolites such as fatty acids, 
nucleosides, and polypeptides.  A theory therefore has been put forward and it suggests that the 
secondary metabolism arose as a way of using the acetate, shikimate and amino acids that were 
excess to requirements (‘shunt metabolites’) (Scott 1974; Zhang and Tang, 2008).  
1.2.2. The Properties of Natural Products  
     The ecological role of natural products among a variety of species results in that natural 
products structures have the characteristic of biochemical specificity, high binding affinities to 
their specific receptor and high chemical diversity (Clardy and Walsh, 2004). Natural products 
are produced in nature, so it is easy and reasonable to assume that all of them have biological 
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functions and they have naturally evolved to be more useful and effective. The generation of 
natural products diversity has occurred not only within the constraints of available biosynthetic 
reaction and precursors but also in the context of biological utility. The biosynthetic routes for 
natural products have coevolved with the functional requirements of their ligands. Natural 
products interact with a wide variety of proteins and other biological targets and they act as 
modulators of cellular processes when they interact with proteins (Koehn and Carter, 2005).  
     Natural products have the highest chemical diversity in nature. Chemical diversity of 
natural products was analyzed in comparison to that of compounds obtained from combinatorial 
chemistry and synthetic drugs derived from natural products.  A large number of compounds 
included 10,968 drug molecues, 670,536 combinatorial compounds, 3,287 natural products and 
27,338 molecules as natural and semi-natural (Feher and Schmidt, 2003). A variety of molecular 
properties, such as number of chiral centers, rotatable bonds, unsaturations, atom types, rings and 
chains were investigated. The result indicated that natural products and combinatorial libraries 
have different properties and natural products are substantially more diverse than combinatorial 
compounds.     
1.2.3. The History of Natural Products in Drug Discovery 
     Natural products have been used in traditional medicines for thousands of years.  Records 
of the first use of natural products were written on clay tablets in cuneiform from Mesopotamia 
about 2600 B.C.; Natural products used were oils of Cedrus species (cedar) and Cupressus 
sempervirens (cypress), Glycyrrhiza glabra (licorice), Commiphora species (myrrh), and 
Papaver somniferum (poppy juice), all of which are still in use today for the treatment of some 
common diseases including coughs, colds, parasitic infections and inflammation (Cragg and 
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Newman, 2005).  
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Figure 1.3 Some important natural products 
In 1804, a 20-year-old pharmacist’s apprentice, Friedrich Sertürner, isolated the first 
pharmacologically active pure compound, Morphine (1), from opium produced by cut seed pods 
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of the poppy, Papaver somniferum. This started an era wherein people isolated, purified, studies 
and administered drugs from medicinal plants in a precise dosage. In 1820, two French 
pharmacists, Caventou and Pelletier, isolated the antimalarial drug, quinine (21), from the bark 
of Cinchona officinalis. Salicylic acid (22) was isolated from the bark of the willow tree (Salix 
alba). These traditional medicines derived mostly from plants formed the basis of most of the 
early medicines (Butler 2004).
  
 
1.2.4. The Rise of Natural Products Research in Drug Discovery 
     The discovery by Fleming in 1928 of penicillin, re-isolation and clinical studies by 
Chain, Florey, and co-workers in the early 1940s together with successful commercialization of 
synthetic penicillins revolutionised drug discovery research.The huge success of penicillin 
prompted a worldwide effort by pharmaceutical industry and academic research to assemble 
large collections of microorganisms in order to discover new antibiotics (Butler 2004).
 
The early 
years were extremely prolific, and included the discovery of streptomycin (23), chlortetracycline 
(24), cephalosporin C, erythromycin (25), and vancomycin (26). All of these compounds or 
derivatives thereof are still used clinically today (Newman et al., 2000). Natural products as 
sources of novel therapeutical agents reached the peak in the pharmaceutical industry in the 
1970s and 1980s (Koehn and Carter, 2005).
 
This was likely due to the breakthrough in the 
1970’s of mechanism-based screening for bioassay-guided fractionation. For example, the β-
lactamase inhibitor, clavulanic acid (27), was identified in the early 1970s using this method 
included from Streptomyces clavuligerus. By 1990, about 80% of drugs were natural products or 
analogues inspired by them (Li and Vederas, 2009).  
1.2.5. The Decline of Natural Products Research in Drug Discovery 
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           Of the 974 small-molecule new chemical entities (NCEs) introduced between 1981-2006, 
about 60% were natural products, semi-synthetic natural product analogues or synthetic 
compounds based on natural product pharmacophore (Newman and Cragg, 2007).   Despite this 
success, natural products research has experienced a slow decline during the past two decades.  
Multiple reasons have been blamed for the decline (Li and Vederas, 2009; Koehn and Carter, 
2005). The main reason is the rapid development of combinatorial chemistry and high-throghput 
screening (HTS) in the pharmaceutical industry (Paterson and Anderson, 2005). 
To date drug discovery and development requires rapid and effective screening, hit 
identification, and hit-lead development. Unfortunately, the traditional resource intensive natural 
product program based on extract-library screening, bioassay-guided fractionation and isolation, 
structure elucidation followed by product scale-up face a huge disadvantage when compared to 
the defined synthetic chemical libraries. 
 
1.2.6. The Renaissance of Natural Products in Drug Discovery 
     Despite the trend in the pharmaceutical industry to downscale its natural product research 
in recent years, there could be change in the wind. The problems with natural products that 
resulted in these initial decisions are being addressed with technological advances, such as 
increasing the throughput of methods for compound purification and identification (Clardy and 
Walsh, 2004). A problem also lies with the unrealized expectations from combinatorial 
chemistry. For a molecular screening library it is imperative that it covers a significant portion of 
chemical diversity, but at the same time be biased toward ‘biological friendliness’ and ‘drug-
likeness’ (Martin 2001). Only very few or no hits were found from some of the first large 
combinatorial libraries which contained more than one million compounds that were synthesized.  
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This was the first mistake of some synthetic chemists, to design the libraries based on chemical 
accessibility and maximum achievable size rather than on biologically-relevant chemical 
diversity or properties.  This was summed up by Danishefsky “a small collection of smart 
compounds may be more valuable than a much larger hodgepodge collection mindlessly 
assembled” (Borman 2002). The potential for undesired side effects resulted from often less 
specific binding characteristics of many of the simple combinatorial generated molecules was 
also a big issue (Paterson and Anderson, 2005). A less specific and weaker activity can be 
obtained by the removal of chiral centers, introducing additinal flexibility into molecules and 
decreasing its size. The greater flexibility of combinatorial compounds is supposed to have 
detrimental entropic consequences for the binding of these compounds and could affect their 
ability to induce conformational changes in the receptor necessary for biological activity.  This 
has prompted a renewed interest in natural products as a source of chemical diversity and lead 
compound generation.  
Natural products tend to have well-defined three-dimensional structures carrying a 
plethora of functional groups.  These have been fine tuned into a precise spatial orientation. The 
structures of the biological targets of natural products (e.g protein binding sites) are often well 
conserved among proteins even having different genetic sequences. The functional group 
diversity and design introduced into natural products during biosynthesis continues to provide 
lessons for chemists in how to construct biologically active mimics and provide selective ligands 
for cellular target (Clardy and Walsh, 2004).  
1.2.7. Fungal Natural Products in Drug Discovery 
     Fungi are widespread throughout most terrestrial ecosystems, and the ecological roles 
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that they play are essential to the maintenance of a healthy biome. Although it is widely known 
that fungi are necessary for degradation of organic matter, the number and complexity of their 
interactions with other organisms is largely overlooked by all but mycologists. Various fungi act 
as pathogens, predators, prey, endosymbionts, exosymbionts, mutualists, commensals, parasites, 
and hosts. Their interactions with other organisms not only enable them to be successful in the 
realm of biology, but also force them to be master chemists. Fungi are relatively simple 
organisms, so communication, exploration, and defense functions must be carried out through 
chemical or biochemical processes. Therefore, fungi would be expected to serve as a prime 
source of novel and functional chemistry.  
     This hypothesis has been supported by the large number of bioactive molecules isolated 
from fungi, some of which have had a vast societal and economic impact. The search for new 
drugs from fungi didn’t start until the discovery of penicillin G (28), a potent antibiotic active 
against Gram-positive bacteria, by Fleming from Penicillium notatum in 1928 and reported in the 
British medical literature in 1929 (Fleming 1929). In 1941, penicillin was first used successfully 
in clinic. The use of penicilin revolutionised the treatment of infectious disease. Many serious 
diseases caused by bacteria could be easily treated. Cephalosporin C (29), originally isolated 
from a fungus Cephalosporium acremonium, also contains the beta lactam ring.  
     Post 1960s, after the excitement that the discovery of penicillin had made, the attention of 
pharmaceutical companies and academic labs drifted away from fungi as a source of lead 
compounds.  Efforts were instead focused on Actinomycetes.  Despite this, it was again a fungus 
that was responsible for the next big breakthrough in medicine.  Cyclosporin A (30), a nonpolar 
cyclic undecapeptide, was isolated from the extract of a soilborne fungus Tolyplocladium 
inflatum (formerly Trichoderma polysporum). It was isolated in 1973 and has since become the 
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prototype of a new generation of immunosuppressants that is used in organ transplantation 
surgery. In the 1980s natural products research met resurgence in the discovery of useful 
compounds from fungal sources, not only for antibiotics but also other therapeutic areas. Success 
stories include the antifungal agent ‘griseofulvin’ (31) from Penicillium griseofulvum and the 
cholesterol biosynthesis inhibitor ‘lovastatin’ (32) from Aspergillus terreus.  
      
 
Figure 1.4 Fungi-derived drugs 
1.3. Biomedical Potential of Fungi-Derived Natural Products with Activities on Opioid or 
Cannabinoid Receptors 
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     According to Schulz et al. in optimizing the search for new bioactive secondary 
metabolites (Schulz et al., 2002), intelligent screenings can prompt a strategy for exploiting the 
untapped potential for secondary metabolites that fungi offer. Radioligand opioid or cannabinoid 
receptors binding assay is one good example of intelligent screenings. This screening method can 
help us explore new chemical scaffolds with good opioid or cannabinoid receptors binding 
affinities from fungi. Currently, only two active compounds were isolated and identified from the 
fungi.  
     In 2002, CJ-15,208 (33) was isolated from the fermentation broth of a fungus, 
Ctenomyces serratus ATCC15502 (Saito et al., 2002; Ross et al., 2010). The in vitro binding 
activity of CJ-15,208 (33) was assessed against the three opioid receptors. It was a modestly 
selective κ ligand: IC50 = 47 nM (κ), 260 nM (μ), 2600 nM (δ); μ/κ ratio = 5.5. The functional κ 
antagonist action of CJ-15,208 (33) was established upon reversal of the κ agonist asimadoline-
suppressed twitch response in a rabbit vas deferens assay: EC50 = 1300 nM. 
 
Figure 1.5 Fungi-derived natural products with activity on opioid receptors 
  
29 
 
     In 1998, a κ opioid receptor binding inhibitor, erinacine E (34), was isolated from the 
fermentation broth of a  basidiomycete, Hericium ramosum CL24240. This compound was a 
highly-selective binding inhibitor for the κopioid receptor: 0.8 μM (IC50) for κ, >200 μM for μ, 
and >200 μM for δ opioid receptor. Further study showed that erinacine E (34) is a κ opioid 
receptor agonist (Saito et al., 1998). 
Most fungi studied to date were isolated from soil and proven to have a variety of new 
and interesting secondary metabolites. All typical soil isolate from genera such as Aspergillus, 
Penicillium, Acremonium and Fusarium, are known for their ability to biosynthesize natural 
products with diverse chemical structures. Interestingly, resource availability and distribution 
have an important role in shaping the composition and functioning of ecosystems, resulting in 
that organism biosynthesize specific secondary metabolites for the ecological needs. Tropical 
storms can greatly affect the net productivity and then soil fertility, which can lead to unusual 
foods. Useful organisms such as fungi may exist on the surface of foods. Humate is comprised of 
humic acid, fulvic acid, minerals, bacteria and fungi, which improve the development of deep 
root system and enhance overall plant health and resistance to diseases. Humate soil has a 
positive role on the physical, chemical, and biological reactions of the soil, inceasing soil fertility 
(Six et al., 2006; Peña-Mendez et al., 2005). 
1.4. The Aim of This Research 
The primary aim of this study was to identify the compounds responsible for the 
biological activity on opioid or cannabinoid receptors of terrestrial fungi collected from Cuba, 
NM and Tifton, GA. Fungal extracts were selected based on the opioid or cannabinoid receptors 
binding affinities assays.  Active compounds were isolated by bioassay-guided fractionation 
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methods. The structure elucidations of purified compounds were carried out using various NMR 
spectroscopy and mass spectrometry techniques.  Absolute configuration of chiral centers in 
compounds were assigned and confirmed by X-ray crystallography, and/or chemical derivation. 
Active compounds were tested by opioid or cannabinoid receptors functional assays to determine 
whether they are agonists or antagonists.  
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2. RESULT AND DISCUSSIONS 
2.1. Bioassay Screening of Fungi Extracts 
    Five fungi species obtained off organge in Tifton, GA in 1978 and one fungi species isolated 
from a humate sample collected in Cuba, New Mexico in 2008 were cultured and extracted. The 
extracts were screened for binding affinities for opioid receptors (subtype δ, κ and μ) and 
cannabinoid receptors (subtype CB1 and CB2) in the radioligand binding assay at the University 
of Mississippi. Active extracts are defined as having ≥ 50% binding affinities for opioid 
receptors (subtype δ, κ and μ) or cannabinoid receptors (subtype CB1 and CB2) in the 
radioligand binding assay. Four species were assayed as active as Table 2.1 showed and then 
were further studied.  
Table 2.1 Binding affinity assay of the isolated three species for human opioid receptors 
(subtype δ, κ and μ) and cannabinoid receptors (subtype CB1 and CB2) 
 
2.2. Bioassay-Guided Fractionation of Selected Fungi 
 
Species  
 
Fractions 
Opioid receptors (%)  Cannabinoid 
receptors (%) 
δ κ μ CB1 CB2 
Eurotium repens  
 
Petroleum 
ether 
62.76 56.52 70.22 60.43 32.06 
Ethyl ether  45.28 16.90 38.43 65.45 57.62 
EtOAc 34.42 21.98 9.31 7.37 10.85 
Acetone 6.18 24.92 -27.85 -56 62.93 
MeOH 24.19 20.91 -27.85 -23.16 46.15 
Neocosmospora 
sp. NRRL 22472 
EtOAc 59.26 28.93 98.78 66.32 43.31 
UK-149 EtOAc 21.70 58.54 12.29 57.30 -49.66 
Eupenicillium 
parvum 
EtOAc 20.30 10.8 56.91 10.5 0.7 
Naloxone 106.40 101.59 96.95 - - 
CP 55,940 - - - 104.3 102.6 
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2.2.1. The Fungus Eurotium repens  
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Figure 2.1 The structures of compounds from the fungus Eurotium repens 
     Bioassay-guided fractionation of the fungus Eurotium repens resulted in the isolation of 
two benzyl derivatives, repenol A (1) and repenol B (2). Seven known secondary metabolites 
were also isolated including five benzaldehyde compounds, flavoglaucin (3) (Miyake et al., 
2009), tetrahydroauroglaucin (4) (Miyake et al., 2009), dihydroauroglaucin (5) (Miyake et al., 
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2009), auroglaucin (6) (Miyake et al., 2009) and 2-(2’,3-epoxy-1’,3’- heptadienyl)- 6-hydroxy-5-
(3-methyl-2-butenyl)benzaldehyde (7) (Wang et al., 2006), one diketopiperazine alkaloid 
echinulin (8) (Slack et al., 2009) and 5,7-dihydroxy-4-methylphthalide (9) (Fujimoto et al., 
1999). The structures of these compounds were established on the basis of extensive 1D and 2D 
NMR spectroscopic analysis and mass spectrometric (ESI-MS) data.  
     Compound 1 was obtained as a yellowish powder, displaying a molecular ion peak at m/z 
303 [M-H]- in the ESI-MS, which in conjunction with NMR data (Table 2.2) indicated the 
molecular formula C19H28O3, thus implying six degrees of unsaturation. The molecular formula 
was subsequently confirmed by the analysis of negative high-resolution ESIMS (m/z 303.1956, 
calcd for C19H27O3, 303.1955). An aromatic singlet at δH 6.72（H-4）and 13C NMR spectra of 1 
showed the presence of a pentasubstituted benzene ring (C-1, 123.0; C-2, 147.7; C-3, 128.5; C-4, 
115.5; C-5, 145.9; C-6, 121.2). The presence of a singlet at δH 4.83 (H-7) for a methylene proton 
in 1H spectrum and HMBC spectra indicated that one substitution on C-1 is –CH2OH. The 
presence of a 3-methyl-2-butenyl substitution on C-3 was confirmed by two singlets at δH 1.76 
and 1.78 for two methyl protons, HMBC and COSY. In the 1H-1H COSY spectrum of 1, the 
correlations from H-2’ to H-1’ and H-3’, H-4’ to H-3’ and H-5’, H-6’ to H-5’ and H-7’ revealed 
contiguous sequence of the proton signals from H-1’ to H-7’, which confirmed the presence of a 
heptadienyl substitution. The coupling constants 16.0 Hz indicated the E-geometry for the double 
bonds at C-1’. The HMBC between C-1’ and C-6, C-2’ and C-6 showed the presence of the 
heptadienyl substitution on C-6. The 13C NMR spectrum exhibited 19 carbon signals attributable 
to three methyls, six methylenes, four methines and six quaternary carbon atoms according to 
DEPT 135º spectrum. The 1H, 13C and DEPT spectra enabled all but three hydrogen atoms and 
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three oxygen atoms of 1, which should be responsible for three hydroxyl groups. Thorough 
analysis of NMR spectral data resulted in the elucidation of 1.  
Table 2.2 NMR data for compound 1 in CDCl3 
Positions  δC , mult δH (J in Hz) HMBC COSY 
1 145.9, qC - - - 
2 121.2, qC - - - 
3 123.0, qC - - - 
4 147.7, qC - - - 
5 128.5, qC - - - 
6 115.5, CH 6.72s C-1’’, 1, 2, 4 - 
7 60.9, CH2 4.83, s C-2, 3, 4 - 
1’ 122.6, CH 6.24, d (16.0) C-1, 3’, 2 2’  
2’ 139.7, CH 5.90, dt (16.0, 7.0) C-2, 3’, 4’ 1’, 3’ 
3’ 33.3, CH2 2.25, q (7.1) C-1’, 2’,4’, 5’ 2’, 4’ 
4’ 28.9, CH2 1.52, m C-6’, 3’, 5’ 3’, 5’ 
5’ 31.5, CH2 1.35, m C-6’ 4’, 6’ 
6’ 22.5, CH2 1.36, m C-5’ 5’, 7’ 
7’ 14.0, CH3 0.94, t (6.6) C-5’, 6’  6’ 
1” 28.9, CH2 3.33, d (7.1) C-4, 5, 6, 2’’, 3’’,  2’’ 
2” 121.9, CH 5.33, t (7.3) C-4’’, 5’’ 1’’ 
3” 133.9, qC - - - 
4” 25.8, CH3 1.78, s C-2’’, 3’’, 5’’ - 
5” 17.8, CH3 1.76, s C-2’’, 3’’, 4’’ - 
 
     Compound 2 was isolated in low yield as a gummy solid. Negative HRESIMS analysis of 
the [M-H]- ion at m/z 315.1978 allowed a molecular formula of C20H27O3 to be assigned to 2 
(calcd for C20H27O3, 315.1955). The 1H and 13C NMR spectra showed that 1 and 2 are similar. 
The main difference between 1 and 2 are that 2 contains one hemiacetal functionality because 
chemical shift of the methine proton (δH 6.08 ppm) and its corresponding carbon (δC 100.5 ppm) 
indicated it must be on a carbon bearing two oxygen substituents, one of which is hydroxyl 
group because an OH resonance with homocorrlations to H-1 was observed at δH 3.11 ppm.  
NMR spectroscopy (1H, 13C, COSY, HSQC, HMBC) (Table 2.3) indicated the structure to be 
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(E)-4-(hept-1-enyl)-7-(3-methylbut-2-enyl)-2,3-dihydrobenzofuran-2,5-diol, which has not been 
reported previously from a natural source. Because 2 did not show detectable optical rotation, the 
structure of 2 was therefore assigned as an enantiomeric mixture.  
Table 2.3 NMR data for compound 2 in CDCl3 
Positions δC , mult δH (J in Hz) HMBC COSY 
1 - - - - 
2 100.5, CH 6.08, m - 3 
3 38.7, CH2 3.40, dd (16.8, 6.4) 
3.07, d (16.8) 
C-3a, C-7a 
C-2, C-3a 
2 
2 
3a 122.7, qC - - - 
4 119.6, qC - - - 
5 147.5, qC - - - 
6 114.9, CH 6.52, s C-4, C-5, C-7a, C-1’’ - 
7 122.5, qC - - - 
7a 149.4, qC - - - 
1’ 123.1, CH 6.37, d (16.2) C-3a, C-4, C-5, C6, C-3’’ 2’ 
2’ 136.0, CH 6.12, dt (16.2, 7.0) C-4, C-3’, C-4’ 1’, 3’ 
3’ 33.8, CH2 2.25, m C-1’, C-2’, C-4’, C-5’ 2’, 4’ 
4’ 29.1, CH2 1.50, m C-2’, C-3’, C-5’, C-6’ 3’, 5’ 
5’ 31.4, CH2 1.36, m C-6’ 4’, 6’ 
6’ 22.5, CH2 1.37, m C-5’ 5’, 7’ 
7’ 14.0, CH3 0.93, t (6.7) C-5’, C-6’ 6’ 
1’’ 27.9, CH2 3.27, d (6.5) C-6, C-7a, C-2’’, C-3’’ 2’’ 
2’’ 121.6, CH 5.31, t (7.4) C-4’’, C-5’’ 1’’ 
3’’ 133.2, qC - - - 
4’’ 25.8, CH2 1.76, s C-2’’, C-3’’, C-5’’ - 
5’’ 17.8, CH2 1.72, s C-2’’, C-3’’, C-4’’ - 
 
     All pure compounds were submitted for binding assays on opioid receptors (subtype δ, κ 
and μ) and cannabinoid receptors (CB1 and CB2). The results are showed in Table 2.4, 2.5, 
Figure 2.2, 2.3, 2.4, and 2.5. Compound 1 selectively inhibited 62.21% specific binding of [3H]-
Enkephlin to CHO-K1 cell membranes expressing human δ–opioid receptors at the concentration 
of 10 μM (IC50 values of 5.4 μM). Compound 2 selectively inhibited 51.39% specific binding of 
[3H]U-69,593 to CHO-K1 cell membranes expressing human κ –opioid receptors at the 
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concentration of 10 μM (IC50 values of 32.4 μM). Compound 3 inhibited 52.50%, 47.96 and 
67.15% specific binding of [3H]-Enkephlin, [3H]U-69,593 and [3H]-DAMGO to CHO-K1 cell 
membranes expressing human δ, κ, μ-opioid receptors at the concentration of 10 μM, 
respectively. Compound 4 inhibited 59.14% specific binding of [3H]-DAMGO to CHO-K1 cell 
membranes expressing human μ–opioid receptors at the concentration of 10 μM. Compound 6 
inhibited 62.56% specific binding of [3H] CP55,940 to CHO-K1 cell membranes expressing 
human cannabinoid receptor 1 (CB1) at the concentration of 10 μM (IC50 values of 15.2 μM). 
However, Compound 5, 7, 8, 9 were inactive at 10 μM. When comparing the activity of 1, 3, 4, 5 
and 6, it is clear that the position and number of trans double bonds in the long-chain substitution 
of 2, 4-dihydroxylbenzyl derivative can affect largely the activities. Functional assay showed that 
compound 1, 2, 4 and 6 are agonists (Table 2.6, Figure 2.6, 2.7, 2.8 and 2.9).  
 
Table 2.4 Binding affinity assay of the isolated compounds (1-6) for human opioid receptors 
(subtype δ, κ and μ) and cannabinoid receptors (subtype CB1 and CB2) 
 
 
 
 
 
 
 
Compound 
Opioid Receptors (%)  Cannabinoid Receptors (%) 
δ κ μ CB1 CB2 
1 62.21 13.89 15.25 na na  
2 -7.25 51.39 -2.07 nt nt 
3 52.50 47.96 67.15 7.29 0.05 
4 -3.68 14.01 59.14 na -0.95 
5 21.57 13.16 16.91 -11.73 10.11 
6 -13.37 1.79 14.28 62.56 43.13 
Naloxone 106.40 101.59 96.95 nt nt 
CP 55,940 nt nt nt 104.3 102.6 
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Table 2.5 IC50 Values of compound 1, 2, 4 and 6 
 
 
Table 2.6 EC50 Values of compound 1, 2, 4 and 6 
 
 
 
 
 
 
 
Figure 2.2 IC50 and Ki values of compound 1 
Compound Opioid Receptors (µM)  Cannabinoid Receptors (µM) 
δ κ μ CB1 CB2 
1 5.4 - - - - 
2 - 32.4    
4 - - 7.5 - - 
6 - - - 14.1 19.9 
Compound Opioid Receptors (µM)  Cannabinoid Receptors (µM) 
δ κ μ CB1 CB2 
1 10.9 - - - - 
2 - 8.2    
4 - - 4.7 - - 
6 - - - 8.9 10.7 
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Figure 2.3 IC50 and Ki values of compound 2 
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Figure 2.4 IC50 and Ki values of compound 4 
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CB1 Binding Compound 6
-8 -7 -6 -5 -4 -3
0
1000
2000
3000
4000
5000
Ki 7.054e-006
IC50 1.411e-005
log [Compound 6] M
%
 S
pe
ci
fic
3 H
 B
in
di
ng
 (C
PM
)
 
CB2 binding Compound 6
-8 -7 -6 -5 -4
300
400
500
600
700
800
IC50 1.999e-005
Ki 9.994e-006
log [Compound 6] M
%
 S
pe
ci
fic
3 H
 B
in
di
ng
 (C
PM
)
 
 
Figure 2.5 IC50 and Ki values of compound 6 
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Figure 2.6 Effect of compound 1 on δ receptor in the functional assay  
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Figure 2.7 Effect of compound 2 on κ receptor in the functional assay  
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Figure 2.8 Effect of compound 4 on µ receptor in the functional assay 
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Figure 2.9 Effect of compound 6 on CB1 and CB2 receptors in the functional assay 
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     The isolated compounds 1-9 were evaluated, for their antibacterial, antifungal, 
antimalarial and cytotoxic activities. The antibacterial activities were tested against 
Staphylococcus aureus, methicillin-resistant S. aureus (MRS), Escherichia coli, Pseudomonas 
aeruginosa, and Mycobacterium intracellulare. None of these compounds showed in vitro 
antibacterial activity against E. coli, P. aeruginosa, and M. intracellulare (data not shown). 
Compounds 3, 4 and 7 exhibited good antibacterial activity against Staphylococcus aureus with 
IC50 values of 14.32, 13.51 and 7.75 μg/mL, respectively, and compounds 1, 3 and 7 were active 
against methicillin-resistant Staphylococcus aureus (MRS) with IC50 values of 11.97, 10.41 and 
5.40 μg/mL, respectively, while the rest of compounds were inactive. Ciprofloxacin was 
included as positive control for antibacterial activity (Table 2.7). The antifungal activities were 
evaluated against a panel of pathogenic fungi (Candida albicans, C. glabrata, C. krusei, 
Cryptococcus neoformans, and Aspergillus fumigatus) associated with opportunistic infections. 
Amphotericin B was included as a standard antifungal drug for comparison. None of these 
compounds showed in vitro antifungal activity against Candida albicans and Aspergillus 
fumigatus (data not shown). Compounds 1, 4, 5, 6 and 7 showed antifungal activity against 
Candida glabrata with IC50 values of 7.17, 6.15, 2.39, 7.33 and 1.13 μg/mL, respectively. 
Compounds 7 and 9 also showed activity against Cryptococcus neoformans with IC50 values of 
5.31 and 18.08 μg/mL, respectively. Among these compounds, only compound 6 exhibited 
moderate antifungal activity against Candida krusei with an IC50 value of 10.93 μg/mL (Table 
2.7). 
     Antimalarial activity was determined in vitro against chloroquine-sensitive (D6, Sierra 
Leone) and chloroquine-resistant (W2, Indo China) strains of Plasmodium falciparum by 
measuring plasmodial LDH activity. Compounds 1, 3, 4, 6 and 7 exhibited moderate antimalarial 
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activities with IC50 values ranging from 1.1 – 3.0 µg/mL (Table 2). Antimalarial activity of 6 was 
stronger than others 6 (IC50 1.8 and 1.1 μg/mL against D6 and W2, respectively). Although 
compound 5 is structurally similar to compound 1, 3, 4, 6 and 7, compound 5 was found to be 
inactive (Table 2.8).  
     Antileishmanial activity against Leishmania donovani promastigotes was determined by 
Alamar BlueTM assay. Most of these compounds showed moderate to mild activities with IC50 
values ranging from 6.2 to 23 μg/mL as depicted in Table 2.8. Compounds 6 and 7 were more 
active than others with IC50 values of 7.5 and 6.2 μg/mL, respectively (Table 2.8). 
     None of these compounds showed any toxicity toward mammalian kidney fibroblast 
(Vero cells). Compound 8 was inactive in all bioassays (Table 2.8). 
     From the results above, we find that all the active compounds (1, 3, 4, 5, 6, and 7) have 
common structures. They all are benzyl derivatives with a dimethyl allyl and a seven carbon 
chain moiety. Concise structure and activity relationships of this type of compounds are 
summarized. For antibacterial activity, the number of double bonds in the seven carbon chain is 
important for maintaining this kind of activity. Compounds lacking a double bond or possessing 
only one double bond are active while compounds possessing two or three double bonds have a 
loss of antibacterial activity (compound 5 and 6 exhibited no antibacterial activity). Furthermore, 
an aldehyde functionality is crucial for selectivity because compound 1 showed antibacterial 
activity against methicillin-resistant S. aureus (MRS) and compound 4 exhibited antibacterial 
activities against Staphylococcus aureus. A double bond is also crucial for maintaining 
antifungal activity. The lack of a double bond in the seven carbon chain can result in the loss of 
antifungal activity against C. glabrata, C. krusei, Cryptococcus neoformans. The aldehyde 
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functionality is not crucial for antifungal activity since compound 1 and 4 have similar antifungal 
activities. For antimalarial activity, the presence of two double bonds leads to the loss of 
antimalarial activity. However, three double bonds allows for the most potent antimalarial 
activity. Aldehyde functionality is not important for this type of activity because compound 1 
and 4 have similar antimalarial activities. Compound 1, 3, 4, 5, 6 and 7 exhibited good 
antileishmanial activity. The compound 7 showed the most potent and the double bonds in the 
chain maintained a high activity (IC50 of compound 6 is 7.5 μg/mL).  
Table 2.7 In vitro Antimicrobial Activity of 1-8 (IC50 in µg/mL)a 
Compounds Antifungal Antibacterial 
C.glabrata C.krusei C.neoformansb S.aureus MRS 
1 7.17 na na na 11.97 
2 na na na 14.32 10.41 
3 6.15 na na 13.51 na 
4 2.39 na na na na 
5 7.33 10.93 na na na 
6 1.13 na 5.31 7.75 5.40 
7 na na na na na 
8 na na 18.08 na na 
Amphotericin B 0.32 0.36 1.23 nt nt 
Ciprofloxacin nt nt nt 0.10 0.10 
 a IC50=  the test concentration that affords 50% inhibition of growth. MRS= 
methicillin-resistant Staphylococcus aureus.  na = not active at the highest test 
concentration of 20 µg/mL. nt = not tested. b Cryptococcus neoformans. 
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Table 2.8 In vitro Antiprotozoal Activity and Cytotoxicity of 1-8 (IC50 in µg/mL) 
 
Compounds 
Antileishmanial Antimalarial Cytotoxicity 
Vero cells L.donovani P. falciparum 
 D6 W2 
1 19 3.0 2.8 nc 
2 23 3.0 2.7 nc 
3 22 2.8 2.3 nc 
4 20 na na nc 
5 7.5 1.8 1.1 nc 
6 6.2 3.0 2.8 nc 
7 na na na nc 
8 na na na nc 
Pentamidine 1 nt nt nt 
Chloroquine nt 0.016 0.155 nt 
Doxorubicin nt nt nt 7.5 
 a IC50 = the test concentration that affords 50% inhibition of growth 
compared to the solvent control. na = not active, nt = not tested, nc = not 
cytotoxic 
 
2.2.2. The Fungus Neocosmospora sp. NRRL 22472 
     Bioassay-guided fractionation of the fungus Neocosmospora sp. NRRL 22472 resulted in 
the isolation of three new resorcyclic acid lactones, neocosmosin A (10), neocosmosin B (11) 
and neocosmosin C (12) (Figure 2.10). Three known resorcylic acid lactones, monocillin IV (13) 
(Shinonaga et al., 2009), monocillin II (14) (Shinonaga et al., 2009) and monorden (15) (Hellwig 
et al., 2003) were also isolated and identified. The structures of these compounds were 
established on the basis of X-ray crystallography, extensive 1D and 2D NMR spectroscopic 
analysis and mass spectrometric (ESI-MS) data. 
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Figure 2.10 Compounds from the fungus Neocosmospora sp. NRRL 22472 
     Compound 13 was obtained as a white amorphous solid. The structure of 13 was 
identified to be monocillin IV by comparison of its spectroscopic data (Shinonaga et al., 2009).  
Furthermore, Compound 13 was confirmed by X-ray crystallography (Figure 2.12). The relative 
configuration of double bond in the ring of 13 is E and the absolute configuration of C-2 is R. 
Neocosmosin A (10) was obtained as a white amorphous solid and the molecular formula was 
subsequently confirmed by the analysis of positive high-resolution ESIMS (m/z 355.1533, calcd 
for C19H24O5Na, 355.1521). 1H and 13C NMR (CDCl3) spectra of 10 are similar to those of 13. 
The only difference is one methoxy group in 13. So HMBC can identify that the methoxy group 
positioned at C-14. So the structure of 10 was confirmed by spectra comparison of 10 and 13.  
Neocosmosin C (12) was obtained as a white amorphous solid and the molecular formula 
was subsequently confirmed by the analysis of positive high-resolution ESIMS (m/z 357.1322, 
calcd for C18H22O6Na, 357.1314). Neocosmosin C is similar to monocillin IV (13) and 1H 
and 13C NMR spectra of 12 and 10 showed that 12 contains additional non-conjugated carbonyl 
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(δC 212.29, C-6) and has no double bond in the ring. Furthermore, the structure of 12 was 
confirmed by X-ray crystallography which showed that the absolute configuration of C-2 is R 
(Figure 2.11).  
     Neocosmosin B (11) was obtained as a white amorphous solid and the molecular formula 
was subsequently confirmed by the analysis of positive high-resolution ESIMS (m/z 371.1461, 
calcd for C19H24O6Na, 371.1471). 1H and 13C NMR spectra of 11 are similar to those of 12. The 
only difference is one methoxy group in 11. So HMBC can identify that the methoxy group 
positioned at C-14. 
Table 2.9 NMR data for compound 10 in CDCl3 
Position(s)  δC , mult δH (J in Hz) COSY HMBC 
1 18.9, CH3 1.40, d (6.5) 2 C-2, C-3 
2 72.9, CH 5.35, m 1, 3 C-5, C-4 
3 37.7, CH2 2.27, 2.63, m 2, 4 C-2,C-1, C-4, C-5 
4 124.5, CH 5.51, m 3,5 C-3, C-6,C-2 
5 135.1, CH 5.46, m 4, 6 C-3, C-6, C-2 
6 32.7, CH2 2.09, m 5,7 C-4,C-5,C-7,C-8 
7 25.2, CH2 1.63, 1.43, m 6,8 C-5, C-6, C-9 
8 22.1, CH2 1.65, m 7,9 C-7, C-6, C-9 
9 40.8, CH2 2.55, 2.39, m 8 C-7, C-8, C-10 
10 208.2, qC - - - 
11 50.2 4.42, 3.51, d (16.8) - C-17, C-13, C-12, C-10 
12 139.1, qC - - - 
13 112.1, CH 6.24, d (2.5) 15 C-11, C-15, C-17, C-14 
14 163.9, qC - - - 
15 100.1, CH 6.44, d (3.5) 13 C-17, C-13, C-14, C-16 
16 166.0, qC - - - 
17 105.7, qC - - - 
18 170.7, qC - - - 
19 55.4, CH3 3.82, s - C-14 
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Table 2.10 NMR data for compound 11 in CDCl3 
Position(s)  δC , mult δH (J in Hz) COSY HMBC 
1 21.4, CH3 1.32, d(6.2) 2 C-2, C-3 
2 72.7, CH 5.18, dq (12.4, 6.3) 1, 3 - 
3 35.1, CH2 1.47, 1.61, m 2, 4 C-1, C-4 
4 21.7, CH2 1.62, m 3,5 C-1 
5 43.7, CH2 2.08, 2.63, m 4 C-4, C-3, C-6 
6 212.9, qC - -  
7 37.3, CH2 3.33, 2.17, dt(17.8, 4.0) 8 C-6, C-8, C-9 
8 17.1, CH2 1.83, 1.98, m 7, 9 C-10 
9 38.5, CH2 2.65, 2.53, m 8 C-8, C-7, C-10 
10 206.8, qC - -  
11 50.5, CH2 4.51, 3.48, d(17.9) - C-10, C-12, C-13, C-17
12 138.0, qC - - - 
13 112.8, CH 6.14, d(2.5) 15 C-14, C-17, C-15, C-11
14 163.9, qC - - - 
15 100.2, CH 6.43, d(2.5) 13 C-16, C-14, C-13, C-17
16 166.2, qC - - - 
17 105.6, qC - - - 
18 171.0, qC - - - 
19 55.4, CH3 3.80, s - C-14 
Table 2.11 NMR data for compound 12 in CDCl3 
Position(s)  δC , mult δH (J in Hz) COSY HMBC 
1 21.4, CH3 1.34, d(6.2) 2 C-2, C-3 
2 72.8, CH 5.18, m 1, 3 - 
3 35.2, CH2 1.47, 1.63, m 2, 4 C-1, C-4 
4 21.7, CH2 1.64, m 3,5 C-1 
5 43.7, CH2 2.10, 2.67, m 4 C-4, C-3, C-6 
6 213.1, qC - -  
7 37.3, CH2 3.33, 2.20, dt(17.8, 4.0) 8 C-6, C-8, C-9 
8 17.1, CH2 1.84, 2.04, m 7, 9 C-10 
9 38.6, CH2 2.68, 2.55, m 8 C-8, C-7, C-10 
10 207.5, qC - -  
11 50.4, CH2 4.53, 3.48, d(17.9) - C-10, C-12, C-13, C-17
12 138.5, qC - - - 
13 113.0, CH 6.07, d(2.5) 15 C-14, C-17, C-15, C-11
14 160.8, qC - - - 
15 103.0, CH 6.37, d(2.5) 13 C-16, C-14, C-13, C-17
16 166.1, qC - - - 
17 105.5, qC - - - 
18 171.0, qC - - - 
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Table 2.12 NMR data for compound 13 in CDCl3 
Position(s)  δC , mult δH (J in Hz) COSY HMBC 
1 19.0, CH3 1.41, d (6.5) 2 C-2, C-3 
2 72.9, CH 5.35, m 1, 3 C-5, C-4 
3 37.8, CH2 2.30, 2.63, m 2, 4 C-2,C-1, C-4, C-5 
4 124.7, CH 5.48, m 3,5 C-3, C-6,C-2 
5 135.2, CH 5.49, m 4, 6 C-3, C-6, C-2 
6 32.6, CH2 2.10, m 5,7 C-4,C-5,C-7,C-8 
7 25.2, CH2 1.63, 1.43, m 6,8 C-5, C-6, C-9 
8 22.3, CH2 1.65, m 7,9 C-7, C-6, C-9 
9 40.8, CH2 2.61, 2.43, m 8 C-7, C-8, C-10 
10 210.2, qC - - - 
11 49.8 4.48, 3.55, d (16.8) - C-17, C-13, C-12, C-10 
12 139.2, qC - - - 
13 112.2, CH 6.24, d (2.5) 15 C-11, C-15, C-17, C-14 
14 160.9, qC - - - 
15 103.0, CH 6.40, d (3.5) 13 C-17, C-13, C-14, C-16 
16 165.7, qC - - - 
17 105.7, qC - - - 
18 170.6, qC - - - 
 
 
Figure 2.11 ORTEP-3 projection of compound 13 with the displacement ellipsoids drawn the 
50% probability level 
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Figure 2.12 ORTEP-3 projection of compound 12 with the displacement ellipsoids drawn the 
50% probability level 
     All of pure compounds were submitted for binding assay on opioid receptors (subtype δ, 
κ and μ) and cannabinoid receptors (CB1 and CB2). The results were showed in Table 2.13, 
2.14, Figure 2.13 and 2.14.  Compound 10 selectively inhibited 44.66% specific binding of [3H]-
Enkephlin to CHO-K1 cell membranes expressing human δ–opioid receptors at the concentration 
of 10 μM and 44.53% specific binding of [3H] CP55,940 to CHO-K1 cell membranes expressing 
human cannabinoid receptor 2 (CB2) at the concentration of 10 μM. Compound 11 selectively 
inhibited 54.89% specific binding of [3H]-Enkephlin to CHO-K1 cell membranes expressing 
human δ–opioid receptors at the concentration of 10 μM (IC50 values of 14.82 μM). Compound 
12 selectively inhibited 47.40% specific binding of [3H] CP55,940 to CHO-K1 cell membranes 
expressing human cannabinoid receptor 1 (CB1) at the concentration of 10 μM. Compound 13 
selectively inhibited 45.67% specific binding of [3H]-Enkephlin to CHO-K1 cell membranes 
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expressing human δ–opioid receptors at the concentration of 10 μM. Compound 14 selectively 
inhibited 63.52% specific binding of [3H]-DAMGO to CHO-K1 cell membranes expressing 
human μ–opioid receptors at the concentration of 10 μM. Compound 15 selectively inhibited 
84.88% specific binding of [3H]-DAMGO to CHO-K1 cell membranes expressing human μ–
opioid receptors at the concentration of 10 μM. Functional assay showed that compound 11 is a 
δ–opioid receptor agonist (Figure 2.15).  
Table 2.13 Binding affinity assay of the isolated compounds (10-15) for human opioid receptors 
(subtype δ, κ and μ) and cannabinoid receptors (subtype CB1 and CB2) 
 
 
 
 
 
 
Table 2.14 IC50 Values of compound 10 and 11 
 
 
 
 
 
 
Compound 
Opioid Receptors (%)  Cannabinoid Receptors (%) 
δ κ μ CB1 CB2 
      
10 44.66 11.42 22.42 - 44.53 
11 54.89 32.65 23.99 - 46.28 
12 -60.33 8.13 41.32 47.4 27.7 
13 45.67 24.67 8.70 - - 
14 -3.13 9.03 63.52 26.2 14.8 
15 -27.82 -55.98 84.88 30.7 13.0 
Naloxone 103.43 105.64 100.10 - - 
CP 55,940 - - - 88.8 90.3 
Compound Opioid Receptors (µM)  Cannabinoid Receptors (µM) 
δ κ μ CB1 CB2 
10 54.86 - - - - 
11 14.62 - - - - 
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Figure 2.13 IC50 and Ki value of compound 10 
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Figure 2.14 IC50 value of compound 11 
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Figure 2.15 Functional analyses of compound 11 
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2.2.3 The Fungus Eupenicillium parvum 
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Figure 2.16 The structures of compounds from the fungus Eupenicillium parvum 
 
     Bioassay-guided of the EtOAc extract of E. parvum led to the isolation of three chromone 
derivatives, including one new compound (Figure. 2.16), and ten mycophenolic derivatives, 
including two new products as well as 4 known compounds. The known compounds were 
identified as 4-methoxy-5-methyl-2-(2-methyl-5-oxotetrahydro-2-furyl)-2,3-dihydrobenzo [2,1-
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6:3,4-c]difuran-8(6H)-one (19) (Carman 1978), (E)-methyl 6-(4,6-dimethoxy-7-methyl-3-oxo-
1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate (20) (Covarrubias-Zúñiga et al., 2003), 
(E)-methyl 6-(4-acetoxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-
methylhex-4-enoate (21) (Carman 1978), (E)-6-(4-acetoxy-6-methoxy-7-methyl-3-oxo-1,3-
dihydroisobenzofuran-5-yl)-4-methylhex-4-enoic acid (22) (Jones and Mills, 1971), 
mycophenolic acid (23) (Danheiser et al., 1986), O-desmethylmycophenolic acid (24) (Jones and 
Mills, 1971), (E)-5-(4,6-dihydroxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-3-
methylpent-3-enoic (25) (Jones et al., 1970), 5,7-dihidroxy-4-methylphtalide (26) (Fujimoto et 
al., 1999), 7-hydroxy-2,5-dimethyl-4H-chromen-4-one (27) (Kashiwada et al., 1984), 
citromycetin (28) (Yamauchi et al., 1987). The structures of theses known compounds were 
determined by comparison of their spectroscopic data with those reported in the literature. The 
13C NMR (Table 2.16) spectroscopic data of compounds 21, 22 and 24 are reported for first time. 
Compound 22 was confirmed by X-ray crystallography (Figure 2.17). The compounds 19-22 are 
new as natural products. 
     Compound 16 was obtained as yellow solid. Its molecular formula C14H12O6 was 
established by HRESIMS based on its [M+H]+ ion at m/z 277.0701 (calc. 277.0712). The IR 
spectrum of 1 showed absorption peaks for carbonyl (1732 and 1661 cm-1), hydroxyl (3252 cm-1) 
functionalities. The 13C NMR spectrum (Table 2.15) and DEPT spectra gave a total of 14 
separate carbon resonances (two methyls, one methylene, two methines, and nine quaternary 
carbons). The 1H NMR spectrum (Table 2.15) displayed the signal of an aromatic methoxyl 
group at δH 3.95, an singlet at δH 12.61 was characteristic of a chelated hydroxyl proton in 
position C-9 in the aromatic ring, H-8 appeared as a singlet at δH 6.40 with the corresponding 13C 
NMR at δC 98.6, the above information gave that fragment as a monosubstituted benzene ring 
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similar those at A-ring in the known flavonoid 8,10-dihydroxy-5-H-isochromeno[4,3-b]chromen-
7-one (Economides and Adam, 1998). The presence of a methyl group at δH 2.06, methylene 
group at δH 5.29 and a vinyl group δH 6.21 revealed similar features to the comparison of 16 and 
the known compound anhydrofulvic acid (Fujita et al., 1999). The connectivities and positions of 
the substituents between the last two fragments were made by HMBC experiments (Figure 2.17) 
thus H-4 at δH 5.33 showed correlations with C-10a, C-3, C-3a; H-8 at δH 6.40 with C-9a, C-6, C-
7 and C-9; the chelated proton at δH 12.61 with C-8 and C-9 and the protons at δH 5.29 showed 
correlation with C-10a, C-3, C-4 and C-4a. Also in the NOESY experiment there isn’t 
correlation between the methoxyl group and H-8, it led confirmed the position of the methoxyl 
group at C-6. Based on the above data, euparvione (16) was identified as 7,9-dihydroxy-6-
methoxy-3-methylpyrano[4,3-b]chromen-10(1H)-one. 
 
Figure 2.17 Relevant HMBC correlations of compound 16 
     Compound 17 was isolated as colourless solid and its molecular formula was determined 
as C17H20O7 by the analysis of negative high-resolution ESIMS (m/z 335.1141, calcd for 
C17H20O7, 335.1141). The 13C NMR (Table 2.16) and DEPT spectra disclosed 17 carbons, which 
were indicative of two lactone signals at δC 174.4 (C-6′) and 172.9 (C-1), four methylene group 
at δC 18.0 (C-1′); 38.0 (C-5′); 38.3 (C-2′) and 70.1 (C-3), the last one corresponding a methylene 
bearing oxygen, an oxygenated methine at δC 72.4 (C-4′), an oxygenated quaternary carbon at δC 
89.3 (C-3′), an aromatic methyl group at δC 11.6, and at δC 61.2 a methoxyl group. The 1H NMR 
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data (see experimental section) were similar to those of mycophenolic acid (Danheiser et al., 
1986), however, compound 17 has the chain saturated and a lactone group in it as well as a 
hydroxyl group δH 4.41 (dd, J = 4.4, 6.7 Hz, H-4′). Correlations in its COSY and HMBC spectra 
led us to conclude that this group was formed involving OH in the acid group at C-6′ and the C-
3′ generating the formation of the lactone ring. The relative stereochemistry of 17 was 
determined from the NOESY spectrum. Important correlations were observed between H-4′, H-
5′a, H-5′b, and H2-2′, No correlation was observed between the methyl group at δH 1.53 CH3-7′, 
leading to the conclusion that there is a trans stereochemistry between H-4′ and CH3-7′. From 
these data, the euparvilactone 17 was deduced to be 7-hydroxy-6-(3'-(2'-hydroxy-3'-methyl-6'-
oxotetrahydrofuran-3'-yl) ethyl)-5-methoxy-4-methylisobenzo furan-1(3H)-one. 
     Compound 18, euparvic acid B, was obtained as colorless oil. The 1H (see experimental 
section) and 13C NMR spectra (Table 2.16) were similar to those of mycophenolic acid 
(Danheiser et al., 1986), with the exception of the absence of a methoxy signal in the 1H NMR 
spectrum and the absence in its 13C NMR of a methylene signal and the remaining methylene 
signal appeared as singlet at δH 2.26, these suggested that the compound 18 it is a nor-
mycophenolic derivative. On the basis of the above evidence, we assigned 18 as (E)-5-(4,6-
dihydroxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-3-methylpent-3-enoic acid. 
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Table 2.15 NMR Spectroscopic Data for compound 16 in CDCl3 
Position. δC δH 
1 64.1 5.29  s 
3 168.6 - 
3a 20.4 2.06  s 
4 94.7 5.33  s 
4a 160.1 - 
5a 148.0 - 
6 126.6 - 
7 154.2 - 
8 98.6 6.40  s 
9 157.6 - 
9a 105.4 - 
10 177.4 - 
10a 100.41 - 
OMe 61.9 3.95  s 
OH --- 6.21  s 
OH --- 12.61 s 
 
Table 2.16 13C NMR Data for compounds 2-4, 6, 7, and 9 (δ in ppm) 
Position. 2a 3b 4a 6c 7b 9b 
1 172.4  174.8 168.5 168.3 169.2 173.2 
3 70.1 70.9 69.0 68.4 63.6 69.3 
3a 144.4 146.3 147.4 146.2 147.0 144.8 
4 117.0 111.4 115.6 122.9 123.3 109.7 
5 163.6 162.2 159.8 162.7 162.8 162.5 
6 121.8 117.3 115.5 129.2 128.8 115.6 
7 153.4 154.9 157.1 146.0 145.6 160.5 
7a 106.5 103.7 102.8 113.5 112.9 102.2 
1′ 18.0 23.0 29.6 23.5 22.9 21.5 
2′ 38.3 123.4 85.6 122.3 122.1 122.4 
3′ 89.3 136.2 85.3 134.5 134.5 133.7 
4′ 72.4 37.2 30.9 34.4 34.2 34.6 
5′ 38.0 180.8 28.4 32.7 32.1d 29.3 
6′ 174.4 16.5 175.9 173.7 169.1 177.6 
7′ 18.5 -- 20.6 16.2 15.0 14.8 
C-4-Me 11.6 11.4 11.0 11.8 10.3 9.9 
OMe-C-5 61.2 -- 59.2 61.2 60.5 -- 
OMe-COOH -- -- -- 51.5 --- -- 
OAc -- -- -- 20.5 
169.0 
19.1 
169.0 
-- 
a Acetone-d6; b MeOD-d4; c CDCl3; d signal assigned by HMBC experiment 
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The 1H and 13C NMR data of the compounds 21, 22 and 24 are reporting now, the structure of 
the compound 7 was confirmed by X-ray crystallography (Figure 2.18). 
 
Figure 2.18 ORTEP-3 projection of compound 7, with the displacement ellipsoids drawn at the 
50% probability level 
     Table 2.17 showed the bioassay result. Compound 16, 19, 23 and 24 selectively inhibited 
41.66%,  45.88%, 44.01% and 41.83% specific binding of [3H]-DAMGO to CHO-K1 cell 
membranes expressing human μ–opioid receptors at the concentration of 10 μM, respectively. 
Compound 18 and 28 selectively inhibited 44.5% and 50.4% specific binding of [3H] CP55,940 
to CHO-K1 cell membranes expressing human cannabinoid receptor 1 (CB1) at the 
concentration of 10 mM, respectively. Compound 22 inhibited 43.95% specific binding of [3H]-
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DAMGO to CHO-K1 cell membranes expressing human μ–opioid receptors at the concentration 
of 10 μM and 43.3% specific binding of [3H] CP55,940 to CHO-K1 cell membranes expressing 
human cannabinoid receptor 1 (CB1) at the concentration of 10 mM. Compound 25 inhibited 
46.55 % specific binding of [3H]-DAMGO to CHO-K1 cell membranes expressing human μ–
opioid receptors at the concentration of 10 μM and 52.2 % specific binding of [3H] CP55,940 to 
CHO-K1 cell membranes expressing human cannabinoid receptor 1 (CB1) at the concentration 
of 10 mM. 
Table 2.17 Binding affinity assay of the isolated compounds (16-28) for human opioid receptors 
(subtype δ, κ and μ) and cannabinoid receptors (subtype CB1 and CB2) 
 
 
 
 
2.2.4. The Fungus UK-149 
     Primary screening showed that the EtOAc extract of UK-149 has good binding affinity 
for human δ receptor. The EtOAc extract was chromatographed on silica gel 60, 70-230 mesh, 
with solvents stepwise from n-hexane to methanol, yielding five fractions (n-hexane, 50% 
hexane in EtOAc, EtOAc, 50% EtOAc in MeOH and MeOH). The second fraction (50% n-
 
Compound 
Human Opioid Receptors (%) Human Cannabinoid Receptors (%) 
δ κ μ CB1 CB2 
16 -24.68 -45.15 41.66 35.3 16.6 
18 -60.86 -81.57 29.95 44.5 10.3 
19 -49.76 -50.26 45.88 -1.1 7.6 
20 -55.63 -52.07 16.70 27.9 1.9 
21 -62.42 -38.83 39.05 11.6 9.5 
22 -41.14 -41.84 43.95 43.3 10.8 
23 -54.06 -34.31 44.01 29.2 19.8 
24 -63.08 -32.81 41.83 2.1 10.5 
25 -44.66 -4.06 46.55 52.5 4.9 
28 -21.42 9.93 36.92 50.4 12.4 
Naloxone 103.43 105.64 100.10 - - 
CP 55,940 - - - 88.8 90.3 
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hexane in EtOAc) is the active fraction, followed by another column chromatography on silica 
gel with solvents stepwise from n-hexane to methanol. All of fractions have no activity. The 
fraction EtOAc: MeOH (50:50) is almost pure and contains a large amount of brefeldin A (29) 
(Figure 2.19) (Wu and Gao, 2008). The amount of this compound is very large and about 10 g 
(the yield is about 50 %).  
Table 2.18 Binding affinity assay of fractions in UK-149 for human opioid receptors (subtype δ, 
κ and μ) 
 
    
  
Figure 2.19 The structure of brefeldin A 
 
Fractions 
Human Opioid Receptors (%) 
δ κ μ 
G-C-149-Hexane 16.1 12.2 22.7 
G-C-149-Hexane/EtOAc (50:50) 36.9 13.8 67.3 
G-C-149-EtOAc 46.7 -19.3 28.8 
G-C-149-EtOAc/MeOH (50:50) 22.2 24.6 24.7 
G-C-149-MeOH 18.9 3.7 20.9 
G-149-HE5050-Hexane -7.6 16.6 -75.1 
G-149-HE5050- Hexane/EtOAc (10:90) -8.9 -9.2 -150.3 
G-149-HE5050- Hexane/EtOAc (20:80) 30.1 13.4 -50.9 
G-149-HE5050- Hexane/EtOAc (30:70) 29.4 1.8 -62.0 
G-149-HE5050- Hexane/EtOAc (50:50) -11.3 16.0 -85.7 
G-149-HE5050- Hexane/EtOAc (80:20) 38.9 21.3 -61.0 
G-149-HE5050- EtOAc/MeOH (50:50) 6.3 11.6 -139.2 
G-149-HE5050-MeOH 9.1 27.9 -103.9 
Naloxone 100.2 101.9 99.8 
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As we know, it is preferable to observe the activity after fractionation. The activity of fractions 
may indicate that the active compounds are defined to one certain compound or a mixture of 
specific compounds with similar physicochemical properties which cause them to separate 
similarly. So it is necessary to purify only the active fractions. However, fractionation of the 
active fractions often results in a decrease or complete loss of biological activity. The 
phenomenon may be explained by two reasons. The first one is that the method used in 
fractionation is not good because the method may cause the decomposition of active compounds 
in the course of fractionation. For example, silica is chemically active for many compounds and 
easily decomposes them, leading to the loss of activity. If happened, the method should be 
changed to prevent the active compounds from decomposition. The second reason is synergism 
of many different compounds that are separated during fractionation. For example, many 
bacteriocins which are antimicrobial peptides from bacteria must function as two-component 
systems to exhibit full activity (Garneau et al., 2002).  
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3. CONCLUSION 
     Receptors are protein molecules that drugs can bind to and initiate their effects. Receptors 
have an important role in drug discovery and development because they can be used as drug 
targets for potential therapeutic agents. Among all of human receptors, the G protein-coupled 
receptors (GPCRs) are the largest superfamily and are supposed to mediate a variety of 
physiological and pathological processes. Therefore GPCRs have been a significant target for 
drug discovery and development. G protein-coupled receptors (GPCRs) have been the most 
important drug targets and about 30% of current drugs molecules are targeting GPCRs.  
     Both opioid and cannabinoid receptors belong to the large superfamily of GPCRs and 
they play an important role in a variety of processes including pain, craving, neurodegeneration, 
metabolic regulation, anxiety and immune function. Therefore, the advances and discoveries in 
opioid and cannabinoid receptors have paved the way for a very exciting future for opioid and 
cannabinoid receptors-based therapies to potentially treat a variety of conditions ranging from 
pain and neurodegenation to obesity.  
     However, the growing realization of the complexity of both opioid and cannabinoid 
receptors regulation in physiological and pathological conditions have discouraged the 
development of new therapeutics that target these two intriguing systems. So it is of significance 
for us to identify new chemical scaffolds which act on opioid or cannabinoid receptors because 
small molecules with novel structures and potent activity can be not only the biological probes to 
uncover what is behind these two receptors and the mystery of many related CNS diseases but 
also the lead for new therapeutics.  
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     Natural products have characteriastic of biochemical specificity, high binding affinities to 
their specific receptor and high chemical diversity. The ecological role of natural products 
endows them with biological functions and natural products have more diverse than 
combinatorial compounds. Furthermore, it is the intensive study of the chemistry and 
pharmacology of the alkaloid morphine from Papaver somniferum L. that led to the 
identification of opioid receptors and the endogenous opioid system. It is the understanding of 
the effects of Δ9-tetrahydrocannabinol and other cannabinoids, the active principles of marijuana 
that led to the identification of cannabinoid receptors and the endocannabinoid system. 
Therefore, the combination of the excellent characteriastics of natural products with the main 
success in opioid and cannabinoid receptors field can promise us that the continuing 
investigation of natural products offers an excellent approach to yield novel agents to treat opioid 
and cannabinoid receptors-based disorders and to find new chemical tools to better elucidate 
their biological mechanism and uncover the mystery of opioid and cannabinoid receptors system. 
Fungi-derived natural products are unexplored and untapped domains for opioid and cannabinoid 
receptors-based drug discovery though fungi have very successful records in pharmaceutical 
industry. Therefore, it is reasonable and feasible to identify new agents which act on opioid or 
cannabinoid receptors from fungi.  
     Radio-ligand binding assay for opioid and cannabinoid receptor has been a useful tool in 
the discovery of novel agents. With the use of this assay, four fungi species were selected and 
subjected to bioassay-guided fractionation affording a total of twenty-nine compounds which are 
identified using standard spectrometric and spectroscopic methods. Two new benzyl derivatives 
(1 and 2) and seven known compounds (3-9) were isolated and identified from the fungus 
Eurotium repens. This kind of benzyl derivative showed good binding affinities and selectivity 
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for opioid or cannabinoid receptors. Compound 1 showed selective binding affinity for human δ–
opioid receptors with an IC50 value of 5.4 μM. Compound 2 exhibit selective binding affinity for 
human κ –opioid receptors with an IC50 value of 32.4 μM. Compound 4 has selective binding 
affinity for human μ–opioid receptors with an IC50 value of 7.5 μM. Compound 6 showed 
selective binding affinity for human cannabinoid receptor 1 (CB1) and 2 (CB2) with an IC50 
value of 15.2 μM and 19.9 μM). The functional assay showed that they all are agonists.  
     Three new (10-12) and three known resorcylic acid lactones (13-15) were isolated from 
the fungus Neocosmospora sp. NRRL 22472 and the bioassay indicated that the resorcyclic acid 
lactones have good activity on opioid or cannabinoid receptors. Compound 11 exhibited 
selective binding affinity for human δ–opioid receptors with an IC50 value of 14.82 μM. 
Compound 14 selectively inhibited 63.52% specific binding of [3H]-DAMGO to CHO-K1 cell 
membranes expressing human μ–opioid receptors at the concentration of 10 μM. Compound 15 
selectively inhibited 84.88% specific binding of [3H]-DAMGO to CHO-K1 cell membranes 
expressing human μ–opioid receptors at the concentration of 10 μM. 
     Three new (16-18) and ten compounds (19-28) were isolated from the fungus 
Eupenicillium parvum and two compounds exhibited good binding affinity for cannabinoid 
receptor 1. Compound 25 inhibited 46.55% specific binding of [3H]-DAMGO to CHO-K1 cell 
membranes expressing human μ–opioid receptors at the concentration of 10 μM and 52.2% 
specific binding of [3H] CP55,940 to CHO-K1 cell membranes expressing human cannabinoid 
receptor 1 (CB1) at the concentration of 10 mM. Compound 28 selectively inhibited 50.4% 
specific binding of [3H] CP55,940 to CHO-K1 cell membranes expressing human cannabinoid 
receptor 1 (CB1) at the concentration of 10 mM.  
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     The fractionation of UK-149 led to the loss of the biological activity of fractions.  A large 
amount of brefeldin A (29) was identified from the fungus UK-149.  
     In conclusion, the research presented in this dissertation highlights the feasibility of 
exploring new structural scaffolds with binding affinities for opioid or cannabinoid receptors 
from fungi. 
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4.  EXPERIMENTAL METHODS 
4.1. General Experimental Procedures 
     All melting points were obtained on a Thomas Hoover Uni-melt Capillary Melting Point 
Apparatus and are uncorrected. All IR spectra were generated neat on an ATI Mattson FT-IR 
using NaCl plates. Optical rotations were recorded using a Rudolph Research Analytical Autopol 
V polarimeter. UV was respectively obtained using a Perkin-Elmer Lambda 3B 
UV/visspectrophotomer. 1H and 13C NMR spectra were obtained on Bruker model AMX 500 
NMR spectrometers with standard pulse sequences, operating at 500 MHz in 1H and 125 MHz in 
13C. The chemical shift values were reported in parts per million units (ppm) from 
trimethylsilane (TMS) using known solvent chemical shifts. Coupling constants were recorded in 
Hertz (Hz). Standard pulse sequences were used for COSY, HMQC, HMBC, TOCSY, NOESY 
and DEPT. High-resolution mass spectra (HRMS) were measured on a Micromass Q-Tof Micro 
mass spectrometer with a lock spray source. Column chromatography was carried out on silica 
gel (70-230 mesh, Merck) and Sephadex LH-20 (Mitsubishi Kagaku, Tokyo, Japan). TLC (silica 
gel 60 F254) was used to monitor fractions from column chromatography. Preparative TLC was 
carried out on silica gel 60 PF254+366 plates (20 × 20 cm, 1 mm thick). Visualization of the 
TLC plastes was achieved with a UV lamp (λ=254 and 365 nm) and anisaldehyde/acid spray 
reagent (MeOH: acetic acid: anisaldehyde: sulfuric acid, 85:9:1:5). All HPLC analyses were 
performed on a Waters LC Module I equipped with a UV detector 486 utilizaing the Millenium 
32 Chromatography Manager software (Waters). An ODS column (Phenomenex Luna C18, 10 × 
250 mm, 5 μm) was used. All HPLC solvents were HPLC grade, filtered through appropriate 
membrances (water through 0.45 µm and organic solvents through 0.22 µm filters) and sparged 
prior to and during analysis with nitrogen at a flow rate of 50 mL/min.  
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     If possible, a single crystal was used for data collection on a Bruker Smart Apex II 
system using Cu Kα radiation with a graphite monochromator, fine-focus sealed tube. The 
crystal was stored at 100 K under cooled nitrogen gas from a KRYO-FLEX low-temperature 
device. APEX II software was used to carry out data collection, indexing, and initial cell 
refinements. All non-hydrogen atoms were displayed in the difference electron density maps. 
Anisotropic displacement parameters were considered in the refinement for all non-hydrogen 
atoms. SAINT software was used to carry out frame integration and final cell refinements. 
SHELXTL, V6.12 software was used to carry out structure solution, refinement, graphics, and 
generation of publication materials. Hydrogen atoms were put in their expected chemical 
positions using the HFIX command and were considered in the final cycles of least-squares 
refinement, with isotropic Uij’s related to the atoms ridden upon. The crystallographic data will 
be deposited in the Cambridge Crystallographic Data Center (CCDC).  
4.2. Fungal Material 
     Most of fungi used were collected in Tifton, GA in 1978 and the fungus Eupenicillium 
parvum was collected in Cuba, NM.  
4.3. Fungi Culture 
     The particular fungus used was plated out on potato-dextrose agar (PDA) that was 
maintained at 24 °C, until discrete fungal colonies appeared. Samples from colonies and kept on 
PDA slants in test tubes at 24 °C, then placed in a 4 °C refrigerator until used. Four voucher 
specimens have been deposited in the culture collection of the Medicinal Chemistry Department, 
University of Mississippi. The fungus was inoculated in flasks containg 50 mL of potato-
dextrose broth (PDB) and cultured for two weeks in stationary phase at 25 °C; then the fungus 
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was seeded onto a medium in each flask consisting of 100 g of shredded wheat, 200 mL of low-
pH Oxoid mycological broth, 2% yeast extract, and 20% sucrose in 2.0 L Fernbach flasks (10 
flasks) followed by incubation for 22 days at 24 °C. 
4.4. Taxonomy Identification of Fungi 
4.4.1. The Fungus Eurotium repens 
     A single-conidium isolate of UK-143 was inoculated onto test media and incubated as 
specified in Klich (2002).  Definitive identification to species was on the basis of beta-tubulin 
sequences: Single-conidium isolate (UK-143-sci3) was grown in ½ strength Difco™ potato 
dextrose broth on an orbital shaker (125 RPM) for seven days at ambient lab temperatures (22-
24oC), after which mycelium was aseptically removed and washed three times with sterile diH20, 
lyophilized, and stored at -80oC until DNA extraction.  Lyophilized mycelium (20 mg) was 
disrupted while frozen with liquid nitrogen in the presence of MP Biomedicals Lysing Matrix A 
(Saloon, OH) in a Fast Prep™ 120 cell disruptor (speed 4 for 20 seconds).  Genomic DNA was 
isolated immediately following tissue disruption using Qiagen DNeasy® Plant Mini Kit (Qiagen, 
Valencia, CA) following the manufacturer’s instructions.  DNA was eluted from the column with 
100 μL of sterile water. Amplification of the β-tubulin partial gene sequence was accomplished 
using primers Bt2a and Bt2b (Glass and Donaldson 1995).  DNA amplification was performed in 
a Stratagene RoboCycler® thermal cycler programmed for one 10 min cycle at 95oC, followed 
by 4 cycles of ramp down annealing (1oC decreased annealing temperature per cycle) consisting 
of one min at 94oC, 90 sec at 68-65oC, and 2 min at 72oC, followed by an additional 26 cycles of 
one min at 94oC, 90 sec at 64oC, and 2 min at 72oC plus a final extension of 10 min at 72oC.  The 
50 μL PCR reactions contained 2 μL genomic DNA preparation, 5 μL 10X Amplitaq® Gold 
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buffer (150 mM Tris-HCL pH 8.0, 500 mM KCL), 1 μL dNTP mix (10 mM per each dNTP), 50 
pmoles of each primer (Bt2a and Bt2b), 4 μL of 25 mM MgCl2 solution, and 0.5 μL (2.5 units) 
Amplitaq® Gold DNA polymerase (Applied Biosystems Foster City, CA).  Amplified DNA was 
purified with Qiagen QIAquick® spin columns and sequenced on both strands using primers 
Bt2a, Bt2b (Glass and Donaldson 1995).  Additional primers were synthesized to obtain full 
sequence in both directions. Sequencing reactions and primer synthesis was performed by 
Eurofins MWG/Operon (Huntsville, AL).  Sequence data was assembled and aligned using 
Sequencher™ 4.9 software (Gene Codes Corp. Ann Arbor, MI).  PCR (Bt2a and Bt2b) primer 
sequences were clipped from the 452 bp β-tubulin partial gene sequence amplified from UK-
143-sci3 and the resulting sequence aligned with β-tubulin partial nucleotide sequences for ex-
type isolates in section Aspergillus (Peterson 2008) using BLASTN 2.2.21 software (Zhang 
2000).   
     Morphological examination by methods of Klich (2002) enabled keying UK-143 to 
couplets separating three species within section Aspergillus: Eurotium amstelodami, E. 
chevaleiri, and E. herbariorum (the latter including segregate species E. repens and E. rubrum).  
Absence of ascospore maturation in culture precluded further resolution by morphology. 
     According to the phylogenetic analysis of Peterson (2008), 15 species are recognized in 
section Aspergillus.  UK-143 β-tubulin partial gene sequence was 100% homologous to 
sequences within the E. repens lineage, including the ex-type isolate (NRRL 13).  Type 
specimens of other closely related lineages within section Aspergillus had 88-95% homology 
with the UK-143 sequence.  Because of possibly paragolous duplication, the phylogenetic utility 
of the β-tubulin region is compromised in Aspergillus sections Emericella, Nigri, and Usti, but 
the region is still of utility for identification to species in section Aspergillus (Peterson 2008).  
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Isolate UK-143 belongs to a group of species which traditionally included (using current 
names) Eurotium amstelodami, E. chevalier, E. montevidense, E. pseudoglaucum, E. repens, E. 
rubrum and E. tonophilum (Raper and Fennel, 1965). Some of these names (E. montevidense, E. 
pseudoglaucum) are now best regarded as synonyms of other names, while others (including E. 
repens), have been accepted as distinct species by some authors but not by others (Klich 2002). 
Peterson (2008) demonstrated the distinctness of E. repens as a species using DNA sequences 
from four loci, including β-tubulin gene sequences.  Natural products from Eurotium species 
have long been a fruitful area for inquiry (e.g., Ishikawa et al., 1985; Slack et al., 2009).  
4.4.2. The Fungus Neocosmospora sp. NRRL 22472 
     A single conidium isolate UK 153-sci1 was plated to 1/2V8 and carnation leaf agar under 
conditions of Nelson 1983.  The isolate produced Fusarium-like microconidia on both media but 
did not produce sporodochia or classic Fusarium macroconidia.  
     Identification of UK153 was on the basis of beta-tubulin and elongation factor-1α partial 
gene sequences: The single conidium isolate (UK 153-sci1) was grown in ½ strength Difco™ 
nutrient broth on an orbital shaker (125 RPM) for six days at ambient lab temperatures (22-24 
oC), after which mycelium was aseptically removed and washed three times with sterile H20, 
lyophilized, and stored at -80o C until DNA extraction.  Eighteen mg of lyophilized mycelium 
was disrupted while frozen with liquid nitrogen in the presence of MP Biomedicals Lysing 
Matrix A (Saloon, OH) in a Fast Prep™ 120 cell disruptor (speed 4 for 20 seconds).  Genomic 
DNA was isolated immediately following tissue disruption using Qiagen DNeasy® Plant Mini 
Kit (Qiagen, Valencia, CA) following the manufacturer’s instructions.  DNA was eluted from the 
column with 100 μL of sterile water.  Amplification of the β-tubulin partial gene sequence was 
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accomplished using primers Bt2a and Bt2b (Glass and Donaldson, 1995).  DNA amplification 
was performed in a Stratagene RoboCycler® thermal cycler programmed for one 10 min. cycle 
at 95o C, followed by 4 cycles of ramp down annealing (1o C decreased annealing temperature 
per cycle) consisting of one min. at 94o C, 90 sec. at 68-65o C, and 2 min. at 72o C, followed by 
an additional 26 cycles of one min. at 94o, 90 sec. at 64o C, and 2 min. at 72o C plus a final 
extension of 10 min. at 72o C.  The 50 μL PCR reactions contained 2 μL genomic DNA 
preparation, 5 μL 10X Amplitaq® Gold buffer (150 mM Tris-HCL pH 8.0, 500 mM KCL), 1 μL 
dNTP mix (10 mM per each dNTP), 50 pmoles of each primer (Bt2a and Bt2b), 4 μL of 25 mM 
MgCl2 solution, and 0.5 μL (2.5 units) Amplitaq® Gold DNA polymerase (Applied Biosystems 
Foster City, CA).  Amplification of the elongation factor (EF)-1α coding region and introns were 
amplified with primers EF-1 and EF-2 (O’Donnell et al., 1998).  PCR reaction components were 
identical to the β-tubulin reactions aside from the gene specific primers and were performed in 
an Applied Biosystems Gene Amp 9700 thermalcyler.  Reaction conditions consisted of a single 
cycle of 10 min. at 95o C followed by 35 cycles of (35 sec. at 94o C, 60 sec. at 64o C, and 2 min. 
at 72o C) plus a final extension cycle of 10 min. at 72o C.  Amplified PCR products were purified 
with Qiagen QIAquick® spin columns.  The 336 nucleotide β-tubulin amplicon was sequenced 
on both strands using primers Bt2a and Bt2b (Glass and Donaldson, 1995).  Additional primers 
were synthesized to obtain full sequence in both directions.  The 743 nucleotide EF-1α partial 
gene was completely sequenced with the amplification primers plus primers EF-11, EF-21, and 
EF-22 (O’Donnell et al., 1998).  Sequencing reactions and primer synthesis was performed by 
Eurofins MWG/Operon (Huntsville, AL).  Sequence data was assembled and aligned using 
Sequencher™ 4.9 software (Gene Codes Corp. Ann Arbor, MI).  The resulting sequences were 
compared to the NCBI nucleotide data base (http://blast.ncbi.nlm.nih.gov) and published 
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sequences belonging to the Fusarium soloni species complex (FSSC) using BLASTN 2.2.21 
software (Zhang et al., 2000).   
     Fusarium soloni sensu lato as defined morphologically (Nelson 1983 and Leslie 2006) is 
a diverse species complex termed FSSC which consists of a growing number of phlylogenetic 
species determined by multi-locus sequence typing (O’Donnell 2000, Chang et al., 2006, and 
Bogale et al., 2009) and biological species based on host specificity and mating types (Matuo 
and Snyder 1973).  FSSC are frequently isolated from soil, decaying plant matter, and are plant 
pathogens to many agriculturally important plants.  FSSC are increasingly associated with 
clinical isolations (Zhang 2006, Manikandan 2007, O’Donnell 2008). 
     Fungal isolate UK 153 resembled typical Fusarium colony morphology in culture and 
produced Fusarium-like microconidia but did not exhibit other morphological characters 
(sporodochia, macroconidia, sclerotia, or chlamydospores) necessary to identify it as a Fusarium 
species.  Βeta-tubulin gene sequence analysis using PCR primers of (Glass and Donaldson 1995) 
allowed us to determine that UK 153 belonged to the genus Fusarium and was a likely candidate 
of the FSSC.  Definitive identification of UK 153 by current phlylogenetic methods (O’Donnell 
et al., 2008, Bogale et al., 2009) required DNA sequence of the elongation factor-1α gene.   
Analysis of EF-1α clearly places UK 153 amongst FSSC Clade 3 (O’Donnell 2000, Bogale et 
al., 2009) with 93-99% identity while sharing only 87-92% identity with FSSC Clades 1 and 2. 
Multilocus haplotype nomenclature applied to the FSSC (O’Donnell et al., 2008, Chang et al., 
2006) further clarifies the phylogenetic relationship amongst Clade 3 FSSC.  UK 153 EF-1α has 
98-99% identity to members of Clade 3, haplotype 8 included in the multi-locus sequence typing 
which identifies it as a Neocosmospora species.  Other haplotypes 1-35 excluding 8 only share 
93-94% identity.   
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     Several Neocosmospora species have been described, some of which are associated with 
a Fusarium solani anamorph.  Neocosmosora vasinfecta E. F. Smith (1899) is the type species 
for the genus (Rossman et al., 1999).  The neotype (BPI 630336) was designated by Cannon and 
Hawksworth in 1984.  EF-1α sequences do not exist in gene bank for the type or neotype 
specimens.   UK 153 EF-1α gene sequence is 100% homologous to a single Neocosmospora sp. 
isolate NRRL 22472 (the only sequence in gene bank with 100% identity) but this isolate was 
not included in the most recent and comprehensive multi-locus haplotype study (O’Donnell 
2008).  Due to the complex and unresolved nature of the FSSC, UK 153 should be referred to as 
Neocosmospora sp. E. F. Smith (1899) within FSSC Clade 3, haplotype 8 (O’Donnel 2008).       
4.5. Chemicals 
     All chemicals used were from Sigma-Aldrich (Poole, Dorset, U.K.) with the following 
exceptions. For the binding experiments, [3H]CP 55,940 (174.8 Ci/mmol), [3H]DAMGO (53.4 
Ci/mmol), [3H]U-69,593 (42.7 Ci/mmol), [3H]Enkephlin (45 Ci/mmol),  were obtained from 
Perkin-Elmer Life Sciences Inc. (Boston, MA, U.S.A.). CP 55,940, DAMGO, DPDPE, nor-
Binaltorphimine and Win 55,212-2 were obtained from Tocris Bioscience (Ellisville, Missouri, 
U.S.A.). 
4.6. Cell Culture 
     CHO-K1 cells (ATCC) were stably transfected via electroporation with full length human 
recombinant cDNA for cannabinoid receptor subtypes 1 and 2 (obtained from Origene). These 
cells were maintained at 37oC and 5% CO2 in a Dulbecco’s Modified Eagles’s medium (DMEM) 
nutrient mixture F-12 HAM supplemented with 2 mM L-glutamine, 10% fetal bovine serum, 
0.5% penicillin–streptomycin, and G418 (600 mg/mL). CHO-K1 cells stably transfected with 
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opioid receptor subtypes µ, δ, and κ were a generous gift from Roth labs (University of North 
Carolina at Chapel Hill, Chapel Hill, N.C., U.S.A.). These cells were maintained at 37oC and 5% 
CO2 in a DMEM nutrient mixture supplemented with 2 mM L-glutamine, 10% fetal bovine 
serum, 0.5% penicillin–streptomycin, and either G418 (600 mg/mL) or hygromycin B (300 
mg/mL). Membranes were prepared by scraping the cells in a 50 mM Tris-HCl buffer, 
homogenized via sonication and centrifuged for 40 minutes at 13650 rpm at 4oC. These were 
kept at -80oC until used for binding assays. Protein concentration was found via Bio-Rad Protein 
Assay (Bradford 1976). 
4.7. Radio-ligand Binding for Cannabinoid Receptor Subtypes 
     All compounds submitted for assay were run in competition binding against both 
cannabinoid receptor subtypes. This followed the methods described previously (Ross et al., 
1999; Thomas et al., 2005).  
     Cannabinoid binding took place under the following conditions.  10 μM of each 
compound was incubated with 0.6 nM [3H] CP 55,940 and 10 μg CB1 or CB2 membrane for 90 
minutes in a silanzied 96-well plate. The reaction was terminated via rapid vacuum filtration 
through GF/C filters presoaked with 0.3% BSA using a Perkin Elmer 96-well Unifilter (Perkin 
Elmer Life Sciences Inc., Boston, Mass. U.S.A.) followed by 10 washes of 50 mM Tris-HCl. 
Plates were read using a Perkin Elmer Topcount (Perkin Elmer Life Sciences Inc., Boston, Mass. 
U.S.A.). Total binding was defined as binding in the presence of 0.1% DMSO.  Nonspecific 
binding was the binding observed in the presence of 10 μM CP55,940. Specific binding was 
defined as the difference between total and nonspecific binding. Percent binding was found with 
the following formula:  
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    100-(Binding of compound- nonspecific binding)*100/specific binding.  
    Ki and IC50 values were calculated using Graph-Pad Prism 5.  
4.8. Radio-ligand Binding for Opioid Receptor Subtypes 
     All compounds submitted for assay were run in competition binding against opioid 
receptor subtypes (δ, κ, µ).  Opioid binding took place under the following conditions: 10 μM of 
each compound was incubated with [3H]-DAMGO (µ),   [3H]-U-69,593 (κ), or [3H]-Enkephlin 
(δ) for 60 minutes in a 96-well plate.  Tritium and   membrane concentration for each cell line 
was determined by saturation experiments performed after each batch of membrane was scraped.   
The reaction was terminated via rapid vacuum filtration through GF/B filters presoaked with 
0.3% BSA using a Perkin Elmer 96-well Unifilter followed by 10 washes of 50 mM Tris-HCl. 
Plates were read using a Perkin Elmer Topcount. Total binding was defined as binding in the 
presence of 0.1% DMSO. Nonspecific binding was the binding observed in the presence of 10 
μM DAMGO (µ), nor-Binaltorphimine (κ), or DPDPE (δ). Specific binding was defined as the 
difference between total and nonspecific binding. Percent binding was found with the following 
formula:  
    100-(Binding of compound- nonspecific binding)*100/Specific Binding.  
    Ki and IC50 values were calculated using Graph-Pad Prism 5.  
4.9. Cell-Based Cannabiniod Receptors Assay  
The functional effects of the compounds on selected human CB1 and CB2 receptor 
subtypes were examined using recently developed sensitive reporter gene assays. 
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The cell-based cyclic-AMP response element-luciferase reporter gene assay (CRE‑LUC) 
was conducted as established recently (Unpublished). CHO cells stably expressing CB1 or CB2 
receptors were transfected with the 6CRE‑LUC plasmid (50 μg/mL) using electroporation (70 
msec, single pulse, 155 volts). The transfected cells were put at a density of 50,000 cells/well in 
microtiter plates (Cultureplate®; Packard) in 200 μL media and allowed to grow for 24 h with 
incubation at 37°C (5% CO2). After 24 h, the cells were treated with different drug 
concentrations for 15 min before stimulation with forskolin (5 µM) for a further 5 h. After drug 
exposures, the cells were lysed, and luciferase activity was measured using the Luclite assay kit. 
Data were normalized relative to luciferase changes of forskolin (5 × 10-6 M = 100%) for all CB 
receptor subtypes. 
4.10. Cell-based Opioid Receptors Functional Assay 
The functional effects of the compounds on selected human δ-, γ-, and κ-opioid receptor 
subtypes were examined using recently developed sensitive reporter gene assays. 
The cell-based cyclic-AMP response element-luciferase reporter gene assay (CRE‑LUC) 
was conducted as established recently  (Unpublished) CHO cells stably expressing µ-, δ-, and κ- 
opioid receptors were transfected with the 6CRE‑LUC plasmid (50 μg/mL) using electroporation 
(70 msec, single pulse, 155 volts). The transfected cells were put at a density of 50000 cells/well 
in microtiter plates (Cultureplate®; Packard) in 200 μL media and allowed to grow for 24 h with 
incubation at 37°C (5% CO2). After 24 h, the cells were treated with different drug 
concentrations for 15 min before stimulation with forskolin (5 µM) for a further 5 h. After drug 
exposures, the cells were lysed, and luciferase activity was measured using the Luclite assay kit. 
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Data were normalized relative to luciferase changes of forskolin (5 × 10-6 M = 100%) for all 
opioid receptor subtypes. 
4.11. [35S] GTPγS Binding Functional Assay 
     Binding took place under the following conditions: 10 μL compounds diluted to the 
desired concentrations in the dose response curve were mixed with a predetermined 
concentration of 300 ul membrane and 40 ul of 0.05 nM 35S-labelled GTP. The final reaction 
volume is 350 ul per well. Plates incubated for 60 minutes at room temperature. The reaction was 
terminated via rapid vaccum filtration through GF/C filters with a Perkin Elmer 96-well Unifilter 
followed by 10 washes of 50 Mm Tris-HCl (Ph=7.4). Plates were read using a Perkin Elmer 
Topcount. Basal binding was defined as binding in the presence of GTPγS buffers. Nonspecific 
binding was the binding observed in the presence of 10 Um unlabelled GTPγS salt. Emax 
binding was defined as binding in the presence of 10 Um of DAMGO (µ), nor-Binaltorphimine 
(κ), or DPDPE (δ). Percent stimulation was measured by the following:  
    (Binding of compound- nonspecific binding)/Emax) * 100.  
     Ki and IC50 values were calculated using Graph-Pad Prism 5.  
4.12. In vitro Antimicrobial Assay 
All organisms used for the biological evaluation of the metabolites from fungi in present 
reseach were obtained from the American Type Culture Collection (Manassas, VA) and include 
the fungi Candida albicans ATCC 90028, Candida glabrata ATCC 90030, Candida krusei 
ATCC 6258, Cryptococcus neoformans ATCC 90113, and Aspergillus fumigatus ATCC 204305 
and the bacteria Staphylococcus aureus ATCC 29213, methicillin-resistant S. aureus ATCC 
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33591 (MRS), Escherichia coli ATCC 35218, Pseudomonas aeruginosa ATCC 27853, and 
Mycobacterium intracellulare ATCC 23068. A modified version of the CLSI (formerly NCCLS) 
methods (Samoylenko et al., 2009) was used to perform susceptibility testing. M. intracellulare 
was tested using a modified method (Franzblau et al., 1998). Samples were serially-diluted in 20 
% DMSO/saline and transferred in duplicate to 96-well flat bottom microplates. Microbial 
inocula were prepared by correcting the OD630 of microbe suspensions in incubation broth to 
afford final target inocula. Amphotericin B (ICN Biomedicals, Ohio) for fungi and ciprofloxacin 
(ICN Biomedicals, Ohio) for bacteria are used as positive controls in each assay. All organisms 
were measured at either 630 nm using the Biotek Powerwave XS plate reader (Bio-Tek 
Instruments, Vermont) or 544ex/590em, (M. intracellulare, A. fumigatus) using the Polarstar 
Galaxy Plate Reader (BMG LabTechnologies, Germany) prior to and after incubation. Percent 
growth was plotted versus test concentration to produce the IC50. 
4.13. In Vitro Antimalarial Activity 
      Antimalarial activity was determined in vitro against chloroquine sensitive (D6, Sierra 
Leone) and resistant (W2, Indo China) strains of Plasmodium falciparum by measuring 
plasmodial LDH activity as described earlier (Makler et al., 1993). Test compounds were 
dissolved in DMSO (2 mg/mL). A 200 μL suspension of P. falciparum culture (2 % parasitemia 
and 2 % hematocrit in RPMI 1640 medium supplemented with 10 % human serum and 60 
μg/mL amikacin) was added to the wells of a 96-well plate containing 10 μL of serially diluted 
samples. The plate was flushed with a gas mixture of 90 % N2, 5 % O2, and 5 % CO2 and 
incubated at 37 °C for 72 h in a modular incubation chamber. Plasmodial LDH activity was 
determined by using MalstatTM reagent (Flow Inc., Portland, OR). Briefly, 100 μL of the Malstat 
reagent was added to 20 μL of the incubation mixture and incubated for 30 min. Then, 20 μL of a 
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1:1 mixture of NBT/PES (Sigma, St. Louis, MO) was added and the plate is further incubated for 
1 h in dark. The reaction was stopped by adding 100 μL of a 5 % acetic acid solution. The plate 
was measured at 650 nm using the EL-340 Biokinetics Reader (Bio-Tek Instruments, Vermont). 
IC50 values were obtained from the dose–response curves generated by plotting percent growth 
versus drug concentration. Chloroquine was included in each assay as positive control. DMSO 
(0.25 %) was used as a vehicle control. 
4.14. In Vitro Antileishmanial Activity 
     The antileishmanial activity of the compounds was measured in vitro against a culture of 
L. donovani promastigotes (Ma et al., 2004). The promastigotes were cultured in RPMI 1640 
medium supplemented with 10 % fetal calf serum (Gibco Chem. Co.) at 26 oC. A 3-day-old 
culture was diluted to 5× 105 promastigotes/mL. Drug dilutions were carried out directly in cell 
suspension in 96-well plates. Plates were incubated at 26 oC for 48 h and growth of leishmania 
promastigotes was determined by the Alamar blue assay as described earlier. Standard 
fluorescence was read on a Fluostar Galaxy plate reader (BMG Lab Technologies) at an 
excitation wavelength of 544 nm and an emission wavelength of 590 nm. Pentamidine and 
amphotericin B were selected to be the positive controls. IC50 values were computed from dose-
response curves as above. 
4.15. In Vitro Cytotoxicity 
     In vitro cytotoxicity was also determined against mammalian kidney fibroblasts (VERO 
cells). The assay was carried out in 96-well tissue culture-treated plates as described earlier 
(Mustafa et al., 2004). Briefly, cells were seeded in the wells of a 96-well plate (25,000 
cells/well) and incubated for 24 h. Samples were added to the wells and then plates were 
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incubated for 48 h. The number of viable cells was measured by neutral red assay. IC50 values 
were determined from dose curves as described above. In this test, doxorubicin was selected as a 
positive control, while DMSO was used as vehicle control. 
4.16. Bioassay-Guided Fractionation of Selected Fungi 
4.16.1. The Fungus Eurotium repens 
     Following incubation, 300 mL of acetone was added to each flask, and the fungus and the 
substrate were homogenized (Super Dispex, Tekmark Co., SD-45). The suspension was filtered 
and then the filtrate was concentrated under a vacuum at <50 °C. The residue was mixed with 
H2O (200 mL), then extracted with EtOAc (500 mL × 3). The EtOAc extracts were combined, 
dried over anhydrous Na2SO4 and concentrated under a vacuum. The EtOAc extract (8.0 g) was 
chromatographed on silica gel 60, 70-230 mesh (400 g), with fractions stepwise eluted with 
petroleum ether, dimethyl ether, ethyl acetate, acetone and methanol, yielding five fractions. 
Bioassay showed that petroleum ether, ethyl ether and acetone fractions exhibited activities. The 
petroleum ether fraction was rechromatographed over a silica gel 60 column into 10 fractions. 
Fraction 1, 2, 3, 4, 9 and 10 exhibited biological activities. Fraction 1 and 2 were combined and 
were chromatographed by a preparative TLC with n-hexane-CHCl3 (8:2) three times, affording 
compound 3 (4 mg) and compound 4 (12 mg). Fraction 3 and 4 were combined and were 
chromatographed by preparative TLC with n-hexane-CHCl3 (7:3) three times, affording 
compound 7 (3 mg) and compound 5 (4 mg). Fraction 9 and 10 were combined and were 
separated on Sephadex LH-20 CC eluting with CHCl3-MeOH (2:1) to afford four subfractions. 
Subfraction 1 showed activities and was purified by HPLC on RP-18 using gradient elution from 
H2O/MeOH (4:6) to afford compound 1 (5.2 mg) and compound 9 (8.0 mg). The dimethyl ether 
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fraction was purified by HPLC using an RP C18 column and a gradient elution from H2O/MeOH 
(4:6) to afford compound 5 (51 mg) and compound 2 (1.8 mg). The acetone fraction was 
separated on Sephadex LH-20 CC eluting with CHCl3-MeOH (2:1) to afford compound 7 (24 
mg).  
Repenol A (1) 
 yellow solid; [α]25D +12 (c 0.5, CHCl3); UV (MeOH)  λmax 265 nm.1H NMR (Table 1, 500 MHz, 
CDCl3-d3); 13C NMR (Table 1, 150 MHz); HRESIMS m/z 303.1956 [M-H]+ (calcd for C19H27O3, 
303.1955). 
Repenol B (2) 
 gummy solid; UV (MeOH) λmax 265 nm.1H NMR (Table 2, 500 MHz, CDCl3-d3); 13C NMR 
(Table 2, 150 MHz); HRESIMS m/z 315.1978 [M-H]+ (calcd for C20H27O3, 315.1955). 
4.16.2. The Fungus Neocosmospora sp. NRRL 22472 
     Following incubation, 300 mL of acetone were added to each flask, and the mycelia and 
the substrate were homogenized (Super Dispex, Tekmark Co., SD-45). The suspension was 
filtered and then the filtrate was concentrated under a vacuum at < 50 °C. The residue was mixed 
with H2O (200 mL), then extracted with EtOAc (500 mL x 3). The EtOAc extracts were 
combined, dried over anhydrous Na2SO4, and concentrated under a vacuum. The EtOAc extract 
(10.0 g) was chromatographed on silica gel 60, 70-230 mesh, with fractions stepwise from n-
hexane to methanol, yielding seven fractions ( 90% hexane in EtOAc, 60 % hexane in EtOAc, 
40% hexane in EtOAc, 10% hexane in EtOAc, 80% EtOAc in MeOH, 50% EtOAc in MeOH and 
MeOH).  The second are third fractions showed good binding affinities for opioid or cannabinoid 
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receptors and then them were combined. The fraction was rechromatographed by silica gel 
column and eluted with hexane-EtOAc gradient to yield 47 fractions. Based on TLC using 
solvent system Hexan-EtOAc (1:1), these 47 fractions was combined into three subfractions. The 
first subfraction was purified by HPLC using an RP C18 column and a gradient elution from 
H2O/MeOH (4:6) to afford compound 10 (10 mg) and compound 11 (3 mg). The second 
subfraction was purified by using an RP C18 column and a gradient elution from H2O/MeOH 
(4:6) to afford compound 12 (8 mg) and compound 13 (25 mg). The third subfraction was 
purified by using an RP C18 column and a gradient elution from H2O/MeOH (4:6) to afford 
compound 14 (3 mg) and compound 15 (4 mg).  
Neocosmosin A (10)  
white amporphous solid; 1H NMR (Table 2.7, 500 MHz, CDCl3-d); 13C NMR (Table 2.9, 150 
MHz); HRESIMS m/z 355.1533 [M+Na]+ (calcd for C19H24O5Na, 355.1521). 
Neocosmosin B (11) 
white amporphous solid; 1H NMR (Table 2.8, 500 MHz, CDCl3-d); 13C NMR (Table 2.10, 150 
MHz); HRESIMS m/z 371.1461 [M+Na]+ (calcd for C19H24O6Na, 371.1471). 
Neocosmosin C (12): white amporphous solid; 1H NMR (Table 2.9, 500 MHz, CDCl3-d); 13C 
NMR (Table 2.11, 150 MHz); HRESIMS m/z 357.1322 [M+Na]+ (calcd for C18H22O6Na, 
357.1314). 
4.16.3. The Fungus Eupenicillium parvum 
     Following incubation, 300 mL of acetone were added to each flask, and the mycelia and 
the substrate were homogenized (Super Dispex, Tekmark Co., SD-45). The suspension was 
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filtered and then the filtrate was concentrated under a vacuum at < 50 °C. The residue was mixed 
with H2O (200 mL), then extracted with EtOAc (500 mL x 3). The EtOAc extracts were 
combined, dried over anhydrous Na2SO4, and concentrated under a vacuum. The EtOAc extract 
(22.0 g) was chromatographed on silica gel 60, 70-230 mesh, with fractions stepwise eluted with 
CH2Cl2-Me2CO mixtures (8:2; 7:3; 1:1), Me2CO, and Me2CO-MeOH (9:1) (each 200 mL), 
yielding thirty fractions. According to the TLC profile 7 major fractions were obtained. Fraction 
1 (300 mg) was submitted to column chromatography using CHCl3-diethyl ether (19:1). 
Obtained two major subfractions, from the first subfraction a precipitate was obtained, it was 
purified by crystallization to give ergosterol (35 mg), from the last subfraction a resorcinol 
derivative (25 mg) was obtained. Fraction 2 (450 mg) was chromatographed over silica gel 60 
column and eluted with hexane-EtOAc gradient, to yield eigth subfractions. Subfractions 1-2 
were rechromatographed by silica gel column using hexane-diethyl ether (8:2) to yield 3β-
hidroxy ergost-5-en-7-one (15 mg). Subfractions 3-6 were combined and rechromatographed 
over silica gel, eluted with CHCl3-EtOAc (9:1) to yield 4-methoxy-5-methyl-2-(2-methyl-5-
oxotetrahydro-2-furyl)-2,3-dihydrobenzo [2,1-6:3,4-c]difuran-8(6H)-one (19, 5 mg). Subfraction 
7-8 (800 mg) were combined and purified by silica gel column using CHCl3-MeOH (19:1) a total 
of six subfraction were obtained. From subfraction 1-2, 7-hydroxy-2,5-dimethyl-4H-chromen-4-
one (27, 4 mg) was isolated. From subfractions 3, a vanillic acid was isolated. Subfractions 4-6 
were purified by silica gel column using CHCl3-MeOH (19:1) and by Sephadex LH-20 using 
CHCl3-MeOH (1:1) to obtained the compounds (E)-methyl 6-(4,6-dimethoxy-7-methyl-3-oxo-
1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate (20, 10 mg), (E)-methyl 6-(4-acetoxy-6-
methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate (21, 15 mg), 
(E)-6-(4-acetoxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzo furan-5-yl)-4-methylhex-4-
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enoic acid (22, 12 mg) and mycophenolic acid (23, 22 mg). Fraction 3 (420 mg) was 
chromatographed by silica gel column using CH2Cl2-isopropanol (8:2) to give the compounds O-
desmethylmycophenolic acid (24, 3 mg), (E)-5-(4,6-dihydroxy-7-methyl-3-oxo-1,3-
dihydroisobenzofuran-5-yl)-3-methylpent-3-enoic (25, 4 mg) and 5,7-dihidroxy-4-
methylphtalide (26, 20 mg). Fraction 4 (550 mg) was chromatographed over silica gel 60 column 
and eluted with hexane-acetone (7:3) gradient, to yield six subfractions. Subfractions 1-2 were 
rechromatographed by Sephadex LH-20 column using hexane-CH2Cl2-MeOH (1:2:2) to yield 
euparvione (16, 4 mg). Subfractions 3-5 were combined and rechromatographed over silica gel, 
eluted with CHCl3-MeOH (9:1) and by TLC preparative CHCl3-MeOH  three times to furnish 
euparvilactone (17, 5 mg) and euparvic acid B (18, 8 mg). From the last subfraction a major 
product was precipitate, it was separated by filtration and it was washing several times with 
CHCl3 to yield citromycetin (28, 20 mg).  
Euparvione (16) 
Yellow powder; IR (KBr) νmax 3252, 2923, 2852, 1732, 1661, 1601, 1574, 1558, 1511, 1470, 
1435, 1397, 1350, 1260, 1168, 1064, 1002 cm-1; 1H NMR (500 MHz, CDCl3) and 13C NMR (125 
MHz, CDCl3) see Table 2.15; HRESIMS m/z 277.0701 [M + H]+ (calcd for C14H13O6, 
277.0712). 
Euparvilactone (17) 
White solid; IR (KBr) νmax xxxx cm-1; 1H NMR (500 MHz, CDCl3): δH 1.53 (3H, s, CH3-7′), 1.89 
(2H, q br, J = 8.9 Hz, CH2-2′), 2.17 (3H, s, CH3-C-4), 2.61 (1H, dd, J = 17.9, 4.7 Hz, H-5′a), 
2.80 (2H, m, CH2-1′), 2.97 (1H, dd, J = 17.9, 6.8 Hz, H-5′b), 3.81 (3H, s, OCH3-C-5), 4.41 (1H, 
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dd, J = 4.4, 6.7Hz, H-4′), 5.23 (2H, s, CH2-3); 13C NMR (125 MHz, CDCl3) see Table 2.16; 
HRESIMS m/z 335.1141 [M-H]+ (calcd for C17H20O7, 335.1141). 
Euparvic acid B (18) 
White solid; IR (KBr) 1H NMR (500 MHz, CDCl3): δH 1.81 (3H, s, CH3-6′), 2.08 (3H, s, CH3-C-
4), 2.26 (2H, s, CH2-4′), 3.38 (2H, d, J = 8.7 Hz, CH2-1′), 5.20 (2H, s, CH2-3), 5.24 (1H, t, J = 
8.6 Hz, H-2′); 13C NMR (125 MHz, CDCl3) see Table 2.16;  
4.16.4. The Fungus UK-149 
     Following incubation, 300 mL of acetone were added to each flask, and the mycelia and 
the substrate were homogenized (Super Dispex, Tekmark Co., SD-45). The suspension was 
filtered and then the filtrate was concentrated under a vacuum at < 50 °C. The residue was mixed 
with H2O (200 mL), then extracted with EtOAc (500 mL x 3). The EtOAc extracts were 
combined, dried over anhydrous Na2SO4, and concentrated under a vacuum. The EtOAc extract 
(20.0 g) was chromatographed on silica gel 60, 70-230 mesh, with fractions stepwise from n-
hexane to methanol, yielding five fractions (n-hexane, 50% hexane in EtOAc, EtOAc, 50% 
EtOAc in MeOH and MeOH).  The second fraction (50% hexane in EtOAc) is the active 
fraction, followed by another column chromatography on silica gel with solvents stepwise from 
n-hexane to methanol. All of fractions have no activity. The fraction EtOAc: MeOH (50:50) is 
almost pure and contains a large amount of brefeldin A (29).The amount of this compound is 
very large and about 10 g (the yield is about 50 %).  
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APPENDIX 
 
1H NMR Spectrum of Repenol A (1) in CDCl3 (500 MHz).
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13C NMR Spectrum of Repenol A (1) in CDCl3 (125 MHz). 
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DEPT 135º Spectrum of Repenol A (1) in CDCl3 (125 MHz). 
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HMQC Spectrum of Repenol A (1) in CDCl3 (500 MHz). 
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HMBC Spectrum of Repenol A (1) in CDCl3 (500 MHz). 
 
 
 
 
 
 
 
 
 
 
 
 
113 
 
COSY Spectrum of Repenol A (1) in CDCl3(500 MHz). 
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 1H-NMR Spectrum of Repenol B (2) in CDCl3(500 MHz). 
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13C-NMR Spectrum of Repenol B (2) in CDCl3 (125 MHz). 
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DEPT 135ºSpectrum of Repenol B (2) in CDCl3 (125 MHz). 
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HMQC Spectrum of Repenol B (2) in CDCl3-d3 (500 MHz). 
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COSY Spectrum of Repenol B (2) in CDCl3 (500 MHz). 
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HMBC Spectrum of Repenol B (2) in CDCl3 (500 MHz). 
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High resolution ESI-MS result of Repenol A (1) . 
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High resolution ESI-MS result of Repenol B (2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
122 
 
1H NMR Spectrum of 3 in CDCl3 (500 MHz). 
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13C NMR Spectrum of 3 in CDCl3 (125 MHz). 
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DEPT 135ºSpectrum of 3 in CDCl3 (125 MHz). 
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HMQC Spectrum of 3 in CDCl3 (500 MHz). 
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HMBC Spectrum of 3 in CDCl3 (500 MHz). 
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COSY Spectrum of 3 in CDCl3 (500 MHz). 
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 1H-NMR Spectrum of 3 in CDCl3(500 MHz). 
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13C-NMR Spectrum of 4 in CDCl3(500 MHz). 
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DEPT 135ºSpectrum of 4 in CDCl3 (125 MHz). 
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HMQC Spectrum of 4 in CDCl3 (500 MHz). 
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HMBC Spectrum of 4 in CDCl3 (500 MHz). 
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COSY Spectrum of 4 in CDCl3 (500 MHz). 
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1H NMR Spectrum of 5 in CDCl3 (500 MHz). 
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13C NMR Spectrum of 5 in CDCl3 (125 MHz). 
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DEPT 135ºSpectrum of 5 in CDCl3 (125 MHz). 
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HMQC Spectrum of 5 in CDCl3 (500 MHz). 
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HMBC Spectrum of 5 in CDCl3 (500 MHz). 
 
 
012345678910111213
f2 (ppm)
20
40
60
80
100
120
140
160
180
200
220
G1-3-2b
HMBC
 
 
 
 
 
 
 
 
 
 
139 
 
COSY Spectrum of 5 in CDCl3 (500 MHz). 
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1H NMR Spectrum of 6 in CDCl3 (500 MHz). 
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13C NMR Spectrum of 6 in CDCl3 (125 MHz). 
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DEPT 135ºSpectrum of 6 in CDCl3 (125 MHz). 
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HMQC Spectrum of 6 in CDCl3 (500 MHz). 
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HMBC Spectrum of 6 in CDCl3 (500 MHz). 
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COSY Spectrum of 6 in CDCl3 (500 MHz). 
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1H NMR Spectrum of 7 in CDCl3 (500 MHz). 
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13C NMR Spectrum of  7  in CDCl3 (125 MHz). 
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DEPT 135ºSpectrum of 7 in CDCl3 (125 MHz). 
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HMQC Spectrum of 7 in CDCl3 (500 MHz). 
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HMBC Spectrum of 7 in CDCl3 (500 MHz). 
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COSY Spectrum of 7 in CDCl3 (500 MHz). 
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1H NMR Spectrum of 9 in CDCl3 (500 MHz). 
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13C NMR Spectrum of 9 in CDCl3 (125 MHz). 
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DEPT 135ºSpectrum of 9 in CDCl3 (125 MHz). 
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1H Spectrum of 10 in CDCl3 (500 MHz). 
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13C Spectrum of 10 in CDCl3 (125 MHz). 
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DEPT 135º Spectrum of 10 in CDCl3 (125 MHz). 
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HMQC Spectrum of 10 in CDCl3 (500 MHz). 
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HMBC Spectrum of 10 in CDCl3 (500 MHz). 
 
 
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
f2 (ppm)
20
40
60
80
100
120
140
160
180
200
220
G-C-153-3-2-4
HMBC
 
 
 
 
 
 
 
 
 
 
160 
 
COSY Spectrum of 10 in CDCl3 (500 MHz). 
 
 
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
f2 (ppm)
1
2
3
4
5
6
7
8
9
G-C-153-3-2-4
DQFCOSY
 
 
 
 
 
 
 
 
 
 
161 
 
1H Spectrum of 11 in CDCl3 (500 MHz). 
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13C Spectrum of 11 in CDCl3 (125 MHz). 
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DEPT 135º Spectrum of 11 in CDCl3 (125 MHz). 
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HMQC Spectrum of 11 in CDCl3 (500 MHz). 
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HMBC Spectrum of 11 in CDCl3 (500 MHz). 
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COSY Spectrum of 11 in CDCl3 (500 MHz). 
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1H Spectrum of 12 in CDCl3 (500 MHz). 
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13C Spectrum of 12 in CDCl3 (125 MHz). 
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DEPT 135º Spectrum of 12 in CDCl3 (125 MHz). 
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HMQC Spectrum of 12 in CDCl3 (500 MHz). 
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HMBC Spectrum of 12 in CDCl3 (500 MHz). 
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COSY Spectrum of 12 in CDCl3 (500 MHz). 
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1H Spectrum of 13 in CDCl3 (500 MHz). 
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13C Spectrum of 13 in CDCl3 (125 MHz). 
 
 
 
0102030405060708090100110120130140150160170180190200210
f1 (ppm)
-5000
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
50000
55000
60000
G-C-153-HE6040-2734-2-5
CARBON
19
.0
22
.3
25
.2
32
.6
37
.8
40
.8
49
.8
72
.9
76
.8
77
.0
77
.3
10
3.
0
10
5.
7
11
2.
2
12
4.
7
13
5.
2
13
9.
2
16
0.
9
16
5.
7
17
0.
6
21
0.
2
 
 
 
 
 
 
 
 
 
175 
 
DEPT 135º Spectrum of 13 in CDCl3 (125 MHz). 
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HMQC Spectrum of 13 in CDCl3 (500 MHz). 
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HMBC Spectrum of 13 in CDCl3 (500 MHz). 
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COSY Spectrum of 13 in CDCl3 (500 MHz). 
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1H Spectrum of 14 in CDCl3 (500 MHz). 
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13C Spectrum of 14 in CDCl3 (125 MHz). 
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DEPT 135º Spectrum of 14 in CDCl3 (125 MHz). 
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HMQC Spectrum of 14 in CDCl3 (500 MHz). 
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HMBC Spectrum of 14 in CDCl3 (500 MHz). 
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COSY Spectrum of 14 in CDCl3 (500 MHz). 
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1H Spectrum of 15 in CDCl3 (500 MHz). 
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13C Spectrum of 15 in CDCl3 (125 MHz). 
 
 
 
-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
-2
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
G-C-153-HE4060-0913-s-1-8-2
Bruker AV400
Carbon 18
.1
4
35
.7
5
46
.5
2
50
.6
0
55
.6
5
70
.9
2
76
.7
3
77
.0
5
77
.3
7
10
3.
96
10
6.
44
11
6.
01
12
9.
67
13
0.
13
13
4.
71
13
6.
10
13
8.
89
15
7.
12
16
2.
68
16
9.
17
19
7.
54
 
 
 
 
 
 
 
 
 
187 
 
DEPT 135º Spectrum of 15 in CDCl3 (125 MHz). 
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HMQC Spectrum of 15 in CDCl3 (500 MHz). 
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HMBC Spectrum of 15 in CDCl3 (500 MHz). 
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COSY Spectrum of 15 in CDCl3 (500 MHz). 
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1H Spectrum of 16 in CDCl3 (500 MHz). 
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13C Spectrum of 16 in CDCl3 (125 MHz). 
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HMQC Spectrum of 16 in CDCl3 (500 MHz). 
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HMBC Spectrum of 16 in CDCl3 (500 MHz). 
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COSY Spectrum of 16 in CDCl3 (500 MHz). 
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1H Spectrum of 17 in CDCl3 (500 MHz). 
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13C Spectrum of 17 in CDCl3 (125 MHz). 
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DEPT 135º Spectrum of 17 in CDCl3 (125 MHz). 
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HMQC Spectrum of 17 in CDCl3 (500 MHz). 
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HMBC Spectrum of 17 in CDCl3 (500 MHz). 
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COSY Spectrum of 17 in CDCl3 (500 MHz). 
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1H Spectrum of 18 in CDCl3 (500 MHz). 
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13C Spectrum of 18 in CDCl3 (125 MHz). 
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DEPT 135º Spectrum of 18 in CDCl3 (125 MHz). 
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HMQC Spectrum of 18 in CDCl3 (500 MHz). 
 
 
 
-1.5-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.0
f2 (ppm)
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
f1
 (
pp
m
)
 
 
 
 
 
 
 
 
206 
 
HMBC Spectrum of 18 in CDCl3 (500 MHz). 
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COSY Spectrum of 18 in CDCl3 (500 MHz). 
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1H Spectrum of 19 in CDCl3 (500 MHz). 
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1H Spectrum of 20 in CDCl3 (500 MHz). 
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1H Spectrum of 21 in CDCl3 (500 MHz). 
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13C Spectrum of 21 in CDCl3 (125 MHz). 
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DEPT 135º Spectrum of 21 in CDCl3 (125 MHz). 
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HMQC Spectrum of 21 in CDCl3 (500 MHz). 
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HMBC Spectrum of 21 in CDCl3 (500 MHz). 
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1H Spectrum of 22 in MeOD-d4 (500 MHz). 
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13C Spectrum of 22 in MeOD-d4 (125 MHz). 
 
 
 
-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
-10000
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
110000
120000
130000
10
.3
46
9
14
.9
72
6
19
.1
59
6
22
.9
07
3
34
.2
18
4
47
.2
58
4
47
.4
28
9
47
.5
99
5
47
.7
69
5
47
.9
39
7
60
.5
26
1
68
.6
36
5
99
.9
84
4
11
2.
88
62
12
2.
06
70
12
3.
26
88
12
8.
85
86
13
4.
53
06
14
5.
64
01
14
6.
96
26
16
2.
79
40
16
9.
10
32
16
9.
17
64
 
 
 
 
 
 
 
 
217 
 
DEPT 135º Spectrum of 22 in MeOD-d4 (125 MHz). 
 
 
 
-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
-30000
-25000
-20000
-15000
-10000
-5000
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
50000
55000
10
.3
47
1
14
.9
72
8
19
.1
60
0
22
.9
04
3
34
.2
14
1
60
.5
25
4
68
.6
37
4
12
2.
06
61
 
 
 
 
 
 
 
 
218 
 
HMQC Spectrum of 22 in MeOD-d4 (500 MHz). 
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HMBC Spectrum of 22 in MeOD-d4 (500 MHz). 
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1H Spectrum of 23 in MeOD-d4 (500 MHz). 
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13C Spectrum of 23 in MeOD-d4 (125 MHz). 
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DEPT 135º Spectrum of 23 in MeOD-d4 (125 MHz). 
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HMQC Spectrum of 23 in MeOD-d4 (500 MHz).  
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HMBC Spectrum of 23 in MeOD-d4 (500 MHz). 
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1H Spectrum of 24 in MeOD-d4 (500 MHz). 
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13C Spectrum of 24 in MeOD-d4 (125 MHz). 
 
 
 
-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
-5
0
5
10
15
20
25
30
35
40
45
50
55
60
65
9.
90
17
14
.8
09
1
21
.4
86
6
34
.6
28
6
46
.9
62
3
47
.1
75
5
47
.3
88
4
47
.6
01
2
47
.8
14
4
48
.0
27
2
48
.2
40
2
69
.3
61
1
10
2.
20
02
10
9.
75
85
12
2.
39
65
13
3.
71
43
13
3.
91
92
14
4.
80
85
16
0.
57
73
N
M
H
-
8
-
4
-
2
b
 
 
 
 
 
 
 
 
227 
 
DEPT 135º Spectrum of 24 in MeOD-d4 (125 MHz). 
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1H Spectrum of 27 in Acetone-d6 (500 MHz). 
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1H Spectrum of 28 in MeOD-d4 (500 MHz). 
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13C Spectrum of 28 in MeOD-d4 (125 MHz). 
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DEPT 135º Spectrum of 28 in MeOD-d4 (125 MHz). 
 
 
 
-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
-2000
-1800
-1600
-1400
-1200
-1000
-800
-600
-400
-200
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
2400
18
.0
74
4
48
.4
76
9
61
.7
15
5
10
3.
64
49
11
2.
46
03
14
2.
30
51
 
 
 
 
 
 
 
 
232 
 
HMQC Spectrum of 28 in MeOD-d4 (500 MHz). 
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HMBC Spectrum of 28 in MeOD-d4 (500 MHz). 
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1H Spectrum of 29 in MeOD-d4 (500 MHz). 
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13C Spectrum of 29 in MeOD-d4 (125 MHz). 
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DEPT 135º Spectrum of 29 in MeOD-d4 (125 MHz). 
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HMQC Spectrum of 29 in MeOD-d4 (500 MHz). 
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HMBC Spectrum of 29 in MeOD-d4 (500 MHz). 
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COSY Spectrum of 29 in MeOD-d4 (500 MHz). 
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